TW212801B - - Google Patents

Download PDF

Info

Publication number
TW212801B
TW212801B TW081109698A TW81109698A TW212801B TW 212801 B TW212801 B TW 212801B TW 081109698 A TW081109698 A TW 081109698A TW 81109698 A TW81109698 A TW 81109698A TW 212801 B TW212801 B TW 212801B
Authority
TW
Taiwan
Prior art keywords
group
methyl
gas
carbonyl
pyridin
Prior art date
Application number
TW081109698A
Other languages
Chinese (zh)
Original Assignee
Boehringer Mannheim Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Italia filed Critical Boehringer Mannheim Italia
Application granted granted Critical
Publication of TW212801B publication Critical patent/TW212801B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

五、發明説明(1 ) 本發明偽鼷於[3 Η , 7 η ]««唑并[3 , 4 - a ] at陡,其製法以 及含有彼等之藥學组成物。 更待定而言,本發明你鼷於式(1)化合物:V. Description of the invention (1) The present invention is characterized by the fact that [3 Η, 7 η] «zozo [3, 4-a] at steep, its preparation method and the pharmaceutical composition containing them. More to be determined, the present invention is based on the compound of formula (1):

S (請先閑^背面之注念餐項再塡寫本頁) 缦濟部中央標準局员工消赍合作社印焚 其中: R為(q-D烷基; Ri為游離或》化羧基,烷氣玻基或氡基.或如式-C0NH(CH2&gt;q _HRaRb之基,其中&lt;1為整數2至4; Ra為氲、Cfk烷基、苄 基;Rb為氫或(Ci-C6)烷基,或者Ra及Rb與氰原子共同形 成吡咯啶-1-基、六氫W;啶-1-基、頃啭-4-基、4-硫代0S 唞-4-基、(C1-C4)烷基六氬吡唞-卜基;1?2為({:3-^7)琛烷基,《,/9或7-吡啶基,視情況被取代 之苯基或雙環(其中苯環與含一雇或多傾S自〇, 原子之雜琛拥合,該雯環藉苯琛連接); 為游離或鹽化羧基或烷氣羰基; D為具1_3镰氮原子之5-或6-貝雜琛,其視情況可® 或2傾胺基、單-(Ci-Ce烷基)按基、單-(c3-c7烯基)按基、 *-· 木纸張尺Λ迎用中阀阈家桴芈(CNS)甲·1規f各(210 X :】97公兌) Λ 6 Β6 212801 五、發明説明(2 ) (請毛閱冶背而之注意事項再塡寫本頁) 單-(c3-c7炔基)胺基、二-(Ci-h烷基)胺基、(Ci-C6烷基 )-(C3-C7烯基)胺基、六氫吡啶-1-基、嗎啭-4-基、吡咯 啶-1 -基。 在本文中,「視情況被取代之苯基」意指苯基取代以1-3個選自下列基之取代基:((^-(:6)烷基諸如甲基、乙基、 丙基、異丙基、第3-丁基;(Ci-cy烷氣基諸如甲氣基、 乙氧基、或丙氧基;(Ci-C4)烷硫基諸如甲硫基、乙«基 :苯氣基;4-羥基苯m基;苯硫基;4-羥基苯硓基;鹵素 原子(氛、溴或氟);氰基、疊氮基、硝基、胺基;(Ci-Ce )醯胺基;三鹵乙醯胺基諸如三氟乙匿胺基;甲-或三«甲 -磺S胺基;苯-或對-甲苯磺醒胺基;三鹵甲基諸如三氯-或三氣甲基;二鹵甲氧基諸如二氟甲m基;三氟甲氧基; 游離或鹽化羧基;(Ci-C 4)烷氯羰基。 較佳之單-或多-取代苯基為擄帶下列取代基者:2-氣、 經濟部中央標準局員工消费合作社印焚 ** SR、4 -累、2,3 - —累、2_ 篇、2 -截-3 -第、2 - ίβ 基、3 *&quot; 硝基、3-硝基-4-苯氧基、4-硝基、4-硝基-3-苯氧基、2-三氟甲基-、3-三氟甲基-、3-«基、3-甲氣基、2-胺基、 3-胺基、4-胺基、2-甲磺酵胺基、3-甲磺醯胺基、4-甲磺 酵胺基、3-甲磺醒胺基-4-苯氣基、4-甲磺醯胺基-3-苯氣 基、4-«-2,3-二氮、3-羧基-4-羥基、3-羥基-4-羧基及 其組合。 當R2S(C3-C7)瓌烷基時,其較好為琛丙基、琛戊基或 環己基。 當1^或卩3為烷氣羰基時,其較好為((^-(:4)烷酯、烯丙 衣紙張尺度適用中家丨?準(CNS)甲!规丨各(21(1 X 297公;f ) 4 Λ(ι Η(; 212801 五、發明説明(3 ) 酯、炔丙酯、苄酯、對-甲氧苄酯、二苯甲酯、三苯甲酯 或三氯乙酯。 當R2為雙琛且其中之苯琛舆5-或6-員雜琢拥合時,其較 好為苯;并-1,3-二氣戊園-4-基,1,4-苯弁二氣戊園-6-基 、:1,4-苯并二氣戊園-5-基、苯并呋喃-4-基、苯并呋阽-4 -基。 ^ D之較佳例有吡啶-2-基、嘧啶-4-基、哺啶-2-基或1,3, 5-三唞-2-基,其可視需要取代以1或2個胺基、單- (Ci-Ce -烷基)胺基、2-丙烯基胺基、2-丙炔基胺基、丙基胺基、 異丙基肢基、或二烷基胺基諸如二甲基胺基、二乙基胺基 、乙基-2-丙烯基胺基等。 待別較佳之D有:吡啶-2-基、[2,6 _贰(二乙基胺基)哺 淀-4-逢―、[2,6-® (2-丙嫌基按基)哺 i®_4-基]、[2,6-¾ (胺基)嘧啶-4-基]、[2,6-贰(吡咯啶-卜基)唯啶-4-基]、 [4,6-贰(2-丙烯基胺基)-1,3,5-三唞-2-基]、[4,6-贰(二 乙基胺基)-1,3,5-三唞-2-基]、[4,6-贰(吡咯啶-:1-基)-1 ,3,5-三唞-2-基]、[3,6-贰(二乙基胺基)tft啶-2-基]、[3 ,6-贰(tt咯啶-1-基)lit啶-2-基]、[3,6-贰(2-丙烯基胺基 )啦淀_2-基]。 經濟部中央標準局员工消費合作社印製 特別較佳之化合物(I)為其中^及^為烷氣羧基,尤其 是甲氧羰基、乙氣羰基、異丙《嫌基、2-丙烯氣羰基及第 3-丁 氧羰基,或者 Ri 為-C0HH(CH2)q-NRaRb 基且 q、Ra 及 Rb 如前文定義,以及R3為如前文定義之烷氣羰基;《2為如前 文定義之視情況取代之苯基或(C3-C 7)瑪烷基;以及R為甲 本纸張尺度適用中家桴準(.CNS)甲見格(210 X 297公璉) ' - 5 A6 212801 _B6_ 五、發明説明(4 ) 基者。 當式(I)化合物中存在酸性或_性基時,其分別可以醫 藥上可接受之鐘或酸鹽化。所生成之無毒鹽,以及單一對 掌異構物、消旋物及非對映異構物、或其潺合物皆包括於 本發明中。更特定而言,式(I)化合物於3-及7-位含有二 不對稱磺原子,同供及對期I幾何構形分別以下列(la)及 (lb)界定: (^叫先間讀背面之注意事項再塡寫本頁)S (please idle ^ memorize the meal on the back and then write this page). The staff of the Central Standards Bureau of the Ministry of Economic Affairs prints and burns the cooperative. Among them: R is (qD alkyl; Ri is free or carboxylated, alkane glass) Group or radon group. Or as in the formula -C0NH (CH2> q _HRaRb group, wherein <1 is an integer 2 to 4; Ra is radon, Cfk alkyl, benzyl; Rb is hydrogen or (Ci-C6) alkyl , Or Ra and Rb together with the cyanide atom to form pyrrolidin-1-yl, hexahydro W; pyridin-1-yl, isop-4-yl, 4-thio-OSS-4-yl, (C1-C4) Alkyl hexahydropyridyl-buyl; 1 to 2 is ({: 3- ^ 7) alkyl, ", / 9 or 7-pyridyl, optionally substituted phenyl or bicyclic (where benzene ring and Containing one or more inclination S from 0, the atoms are mixed together, the Wen is connected via benzene); It is a free or salted carboxyl group or alkane carbonyl group; D is 5- or 6- with 1_3 sickle nitrogen atom Bezachen, which may be ® or 2-tilt amine group, mono- (Ci-Ce alkyl) group, mono- (c3-c7 alkenyl) group, *-· wood paper ruler Λ Valve Threshold Jiahuan (CNS) A · 1 gauge f each (210 X:】 97 public exchange) Λ 6 Β6 212801 V. Description of the invention (2) (Please read the notes on the back (Write this page) Mono- (c3-c7 alkynyl) amine, di- (Ci-h alkyl) amine, (Ci-C6 alkyl)-(C3-C7 alkenyl) amine, hexahydropyridine -1-yl, moxi-4-yl, pyrrolidin-1-yl. In this context, "optionally substituted phenyl" means phenyl substituted with 1-3 substituents selected from the following groups: ((^-(: 6) alkyl such as methyl, ethyl, propyl, isopropyl, 3-butyl; (Ci-cy alkanoyl such as methyl, ethoxy, or propoxy ; (Ci-C4) alkylthio groups such as methylthio, ethyl «group: benzene gas group; 4-hydroxybenzene m group; phenylthio group; 4-hydroxyphenyl group; halogen atom (ambient, bromine or fluorine); Cyano, azide, nitro, amine; (Ci-Ce) amide group; trihaloacetamide group such as trifluoroethyl amine group; methyl- or tri «methyl-sulfonyl amine group; benzene- Or p-toluenesulfonamide; trihalomethyl such as trichloro- or trifluoromethyl; dihalomethoxy such as difluoromethyl m; trifluoromethoxy; free or salted carboxyl groups; (Ci- C 4) Alkyl chlorocarbonyl group. The preferred mono- or poly-substituted phenyl groups are those with the following substituents: 2-gas, printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs * * SR, 4-tired, 2, 3--tired, 2_ articles, 2-cut -3-first, 2-ίβ group, 3 * &quot; nitro, 3-nitro-4-phenoxy, 4- Nitro, 4-nitro-3-phenoxy, 2-trifluoromethyl-, 3-trifluoromethyl-, 3- «yl, 3-methyloxy, 2-amino, 3-amino , 4-amino, 2-methanesulfonamido, 3-methanesulfonamido, 4-methanesulfonamido, 3-methanesulfonamido-4-benzyl, 4-methanesulfonamide Yl-3-phenylamino, 4-«-2,3-diazepine, 3-carboxy-4-hydroxy, 3-hydroxy-4-carboxy, and combinations thereof. When R2S (C3-C7) oxalyl is preferred, it is preferably propyl, pentyl or cyclohexyl. When 1 ^ or P3 is an alkyl carbonyl group, it is preferably ((^-(: 4) alkyl ester, allyl-coated paper. Applicable to the Chinese standard? Standard (CNS) A! Regulations 丨 each X 297 male; f) 4 Λ (ιΗ (; 212801 V. Description of the invention (3) Ester, propargyl ester, benzyl ester, p-methoxybenzyl ester, diphenylmethyl ester, triphenylmethyl ester or trichloroethyl Ester. When R2 is Shuangchen and one of the Benzene and 5- or 6-members is conjugated, it is preferably benzene; and -1,3-dioxol-4-yl, 1,4- Benzodiazepine-6-yl, 1,4-benzodiazepine-5-yl, benzofuran-4-yl, benzofuran-4-yl. ^ Preferred examples of D There are pyridin-2-yl, pyrimidin-4-yl, piperidin-2-yl or 1,3,5-tris-2-yl, which can be substituted with 1 or 2 amine groups, mono- (Ci- Ce -alkyl) amino, 2-propenylamino, 2-propynylamino, propylamino, isopropyl leg, or dialkylamino such as dimethylamino, diethyl Amino group, ethyl-2-propenylamino group, etc. Other preferred D are: pyridin-2-yl, [2,6 _2 (diethylamino) diurethane-4-every-, [2 , 6-® (2-propanyl-based) -i-4-_yl], [2,6-¾ (amino) pyrimidin-4-yl] [2,6-Second (pyrrolidinyl-bromo) -pyridin-4-yl], [4,6-Second (2-propenylamino) -1,3,5-tris-2-yl], [4,6-Two (diethylamino) -1,3,5-tris-2-yl], [4,6-Two (pyrrolidin-: 1-yl) -1,3,5- Trim-2-yl], [3,6-II (diethylamino) tft pyridin-2-yl], [3, 6- II (tt pyridin-1-yl) lit pyridin-2-yl ], [3,6-Two (2-propenylamino) ladian_2-yl]. The particularly preferred compound (I) printed by the employee consumer cooperative of the Central Standards Bureau of the Ministry of Economic Affairs is ^ and ^ is alkane carboxyl , Especially methoxycarbonyl, ethylcarbonyl, isopropyl, 2-propylenecarbonyl and 3-butoxycarbonyl, or Ri is -C0HH (CH2) q-NRaRb and q, Ra and Rb are as before Definitions, and R3 is an alkyl carbonyl group as defined above; "2 is an optionally substituted phenyl or (C3-C 7) alkane group as defined above; and R is a paper standard applicable to the domestic standard (.CNS) Jiajiange (210 X 297 Gonglian) '-5 A6 212801 _B6_ V. Description of the invention (4) The base. When there is an acidic or _ sex group in the compound of formula (I), it can be used in medicine Acceptable bell or acidification. The resulting non-toxic salts, as well as single para-isomers, racemates and diastereomers, or their complexes are included in the present invention. More specifically, the compounds of formula (I) are in 3- and The 7-position contains two asymmetric sulfon atoms, the same supply and the geometric configuration of phase I are defined by the following (la) and (lb) respectively: (^ Call to read the precautions on the back and then write this page)

(la)-同側 (lb)-對側 經濟部中央標準局員工消費合作社印製 式(la)化合物在下文中被稱為同倒- [3H, 7H]曠唑并[3 ,4 - a ]吡啶,或簡稱為[3 Η , 7 Η ] ««唑并[3 , 4 - a ]吡啶。式 (I b)化合物將被稱為對僱- [3H, 7H]曛唑并[3,4-a]吡啶 ,而非對映異構物混合物将以(s, a)-[3H, 7H]噻唑并[3, 4-a] ttt啶表示。 得自消旋二氫吡啶之式(I a)化合物及式(I b)化合物均 為消旋混合物。光學活性化合物(I a)被定義為(R)-或(S) 本紙張尺度適用中國0家桴準(CNS〉甲4規格(210 X 297公货) 6 212801 Λ«; Bfi 五、發明説明(5 ) -同倒-[3 Η , 7 Η ] &lt;«唑并[3 , 4 - a ]吡啶,或簡稱為(R )或(S ) -[3 Η , 7 Η ]噻唑并[3 , 4 - a ]吡啶;化合物(I b )被稱為(1〇-或(S )-對御| [ 3 Η , 7 Η ]毺唑并[3 , 4 - a ]吡啶。 本發明之式(I )化合物藉下法製備:令如式Ua)或 -(I b)之米契爾(Michael)受腥:(la) -Identical side (lb) -The compound printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs (la) compound is referred to hereinafter as Tong inverted-[3H, 7H] Kuangzo [3, 4-a] Pyridine, or abbreviated as [3 Η, 7 Η] «« zo [3, 4-a] pyridine. The compound of formula (I b) will be referred to as p-employed- [3H, 7H] thiazolo [3,4-a] pyridine, and the mixture of diastereoisomers will be represented by (s, a)-[3H, 7H ] Thiazolo [3, 4-a] ttt pyridine said. The compound of formula (I a) and the compound of formula (I b) obtained from racemic dihydropyridine are racemic mixtures. The optically active compound (I a) is defined as (R) -or (S). The paper size is applicable to China ’s 0 standard (CNS> A4 specifications (210 X 297 public goods) 6 212801 Λ «; Bfi V. Description of the invention (5) -Toggle- [3 Η, 7 Η] &lt; «azolo [3, 4-a] pyridine, or abbreviated as (R) or (S)-[3 Η, 7 Η] thiazolo [3 , 4-a] pyridine; compound (I b) is called (1〇- or (S)-pie Royal | [3 Η, 7 Η] zazolo [3, 4-a] pyridine. The formula of the present invention (I) The compound is prepared by the following method: Let Michael of formula (Ua) or-(I b) be affected:

Hal 'C:Hal 'C:

:C Η - C: -C - C〇2R^ (Ila C〇2r4 (Hb) [其中Hal為齒素原子(氦、溴或磺),以及R4為(Ci-CJ 院基] 與如式(I )之1,4 -二氫吡啶反應:: C Η-C : -C-C〇2R ^ (Ila C〇2r4 (Hb) [where Hal is a halogen atom (helium, bromine or sulfonate), and R4 is (Ci-CJ 院 基) and the formula ( I) 1,4-dihydropyridine reaction:

R! ch2s-r5 Η (III) -----------------1'------¾------.玎 經濟部中央標準局員工消費合作社印ii [其中1{及1^2如前文定義;h ’及之定義WR1&amp;R3,不 遇不為游離或邇化羧基;R5為氫或式c(=NH)-NH2或c (=ΝΗ) - ΗΗ2 · H + P—基(其中P-為無機或有機酸諸如鹽酸 、氳溴酸、乙酸、樺腦磺酸、苯乙酵酸、酒石酸或0, 〇’-二苄醯基酒石酸之平衡離子)]。 本紙if&lt;·又Ttii用中《Η'ί:作準(CNS)甲.1巩格(210 X 297公坌) 7 經濟部中央標準局負工消費合作社印焚 Λ 6 B6_ 五、發明説明(3 ) 式(I )化合物舆式(m)化合物之反應通常於適當鐮存在 下,在情性溶剤中進行,以得到式(Ic)化合物:R! Ch2s-r5 Η (III) ----------------- 1 '------ ¾ ------. Employee consumption of Central Bureau of Standards, Ministry of Economic Affairs Cooperative Society Seal ii [where 1 {and 1 ^ 2 are as defined above; h 'and its definition are WR1 & R3, and are not free or carboxyl groups; R5 is hydrogen or the formula c (= NH) -NH2 or c (= ΝΗ )-ΗΗ2 · H + P- group (wherein P- is an inorganic or organic acid such as hydrochloric acid, rabronic acid, acetic acid, betulinic acid, phenylacetate, tartaric acid or 0, 〇'-dibenzyl tartaric acid Counter ion)]. The paper if &lt; · and Ttii is used in "Η'ί: Zuo Zhun (CNS) A.1 Gongge (210 X 297 public) 7 Ministry of Economic Affairs Central Standards Bureau Negative Work Consumer Cooperative Printing and Burning Λ 6 B6_ V. Description of invention (3 ) The reaction of the compound of formula (I) and the compound of formula (m) is usually carried out in the presence of a suitable sickle in an emotional solution to obtain the compound of formula (Ic):

(其中R, R’i, R2. R'3及R4如前文定義) 該式(Ic)化合物為同俩/對倒非對映異構物混合物形式, 同倒非對映異構物占優勢。然後將生成之式(Ic)化合物分 離成單玀的非對映異構物,或箱下列習知反應將彼等轉變 成式(I )化合物: a) 将羧醱基水解成對«之羧基,然後再将其轉變成號珀 酵亞胺酯、酵基氯化物、混合酐或其他已知之反應性羧基 衍生物;習用水解步»包含,例如.用甲酸銨、Pd/C及三 苯膝水解烯丙《羰基;齡性水解甲®羰基或乙氧羰基;用 三甲矽烷_化物水解第3-丁氧羰基等; b) 將酸或其得自a)之反《性衍丰物與如式H2N-(CH2)q- c) 將游離或蘧化羧基或其對應混合酐或羧酯基通原成一 级酵(CH20H);適當的邇原劑包含二堋烷或者鐮金羼或_ 土金羼之硼«化物; 衣纸張又度適用中阀园家桴準(CNS)甲4丨見格(210 X 2耵公货) 8 -----------------為------裝------訂 (諳先閲汸背面之注意事項再塡寫本頁) Λ 6 E36 五、發明説明(7 ) d)得自c)之酵藉與硫羰二眯唑反應,激而與如式(iv)之 胺:(Wherein R, R'i, R2. R'3 and R4 are as defined above) The compound of formula (Ic) is in the form of a mixture of two / pival diastereoisomers, with the pival diastereomers predominant . The resulting compound of formula (Ic) is then separated into mono-diastereomers, or the following conventional reactions convert them to compounds of formula (I): a) Hydrolysis of the carboxyl group to the «carboxyl group of« , And then convert it into peroximine, fermented chloride, mixed anhydride or other known reactive carboxyl derivatives; conventional hydrolysis step »contains, for example, with ammonium formate, Pd / C and triphenylene Hydrolysis of allyl carbonyl; age-hydrolyzed methyl carbonyl or ethoxycarbonyl; hydrolysis of the third 3-butoxycarbonyl group with trimethylsilyl sulfide, etc .; b) acid or its derivative derived from a). Formula H2N- (CH2) q- c) The free or carboxylated carboxyl group or its corresponding mixed anhydride or carboxyester group can be converted into a primary enzyme (CH20H); a suitable raw material agent includes dialkylene or fumazine or _ soil Jin Yizhi's boron «chemicals; clothing and paper are also suitable for Zhongyuanyuan Jiazheng (CNS) A 4 丨 see grid (210 X 2 public goods) 8 -------------- --- for ------ installed ------ ordered (know the notes on the back of 汸 first and then write this page) Λ 6 E36 V. Description of the invention (7) d) from c) Fermentation reacts with thiocarbendazole to stimulate amines of formula (iv) :

HNHN

N - D (IV) 反應,而被轉變成本發明之式(I)化合物。 e) 將式(Ic)化合物中可能存在之芳族硝基還原,以得到 胺基; f) 得自e)之胺基葙與羧酸、烷基磺酸或芳基磺酸之鹵化 物或酐反應而睡化.得到對應之醯胺及磺隹胺; S)根據習用方法鹽化及/或分離光學、幾何或非對映異 溝物。 式U )化合物與式(H )化合物之反應涉及式(Va)或(Vb) 中間物之生成: R.N-D (IV) reaction, and converted into the compound of formula (I) of the invention. e) reduction of the aromatic nitro group that may be present in the compound of formula (Ic) to obtain an amine group; f) the halide of the amine group obtained from e) and carboxylic acid, alkylsulfonic acid or arylsulfonic acid or The anhydride reacts and falls asleep. The corresponding amides and sulfonamides are obtained; S) Salting and / or separation of optical, geometric or diastereoisomers according to conventional methods. The reaction of the compound of formula U) with the compound of formula (H) involves the formation of an intermediate of formula (Va) or (Vb): R.

2。一^2_ CVa) 'Hal2. A ^ 2_ CVa) 'Hal

經濟部中央標準局員工消費合作社印鉍 'C〇2R4 n^^CH2S-CH=CH-C〇2R4 Η CVb) 此等中間物未經分離直接被琢化成式(I c)化合物。 如式(I)之米契爾受髁為已知或可藉習知方法製備;彼 等中有些在市面上有售。更待定而言,式(H)化合物中曾 本纸張又度通用中家作準(CN'S)甲.1規格(210 X 297公; Λ() 212801 五、發明説明(s) 被提及者有:a)丙炔酸酯;b)a-鹵代丙烯酸酯(藉将丙烯 酸酯與齓素行加成反應,缈而脱鹵化氫而得)。 如式(I )之 1,4-二氫 ft 啶在》087/00836(12.02.1987)中 為己知,或者彼等可根據國際專利申請案中所述之方法裂 備。該式(I)化合物可以消旋物及純對擎異構物之形式使 Μ 用。式U)化合物之純對箪異構物之有用裂法包含根據 ΕΡ90102951.2(15.02,1990)所述之方法,光學解析其與光 學活性酸所形成之異硫脲a。 如式(IV)之六氫at唞被述於W087/01706(26.03,1987)中。 本發明化合物被發現在預防及/或降低呼吸道之過度反 應性以及在治療與支氣管黏膜之急性及亞慢性發炎有鼷之 炎症上有效。 支氣管之遇度反應性為氣嗤之睡床症狀,一般相倍其由 支氣管黏膜之異常潛在收縮及敏感直接迪成。 支氣管之通度反鏖性在遲勘,及/或暴霉於外在刺激如 吸入煙赛、污物、過敏原及内分泌物後,會引發急性氣明 之危象。 經濟部t央標準局β工消費合作社印製 支氣管之過度反匾狀況可藉實驗棋型棋擬,其包含將 PAF(600ju g/JL )輸注人重400〜450g之雄天竺鼠鼸内,該 雄天竺鼠被保持在人工呼吸及胺甲酸乙醱舆溴化帕烏龍 (pancuroniu· bromide)之麻醉下。 PAF,其為氣道發炎遇程中最重要之媒介之一,在輸注1 小時後,引起對各種特殊物質之遇度反應(支氣管收缩)。 本發明化合物在上述_理實驗棋型中之活性以對PAF誘 本纸張尺片a用中H3S家榨準(CNS) f .1規恪(210 X 297公货) _The Ministry of Economic Affairs, Central Bureau of Standards, Employee and Consumer Cooperatives printed bismuth 'C〇2R4 n ^^ CH2S-CH = CH-C〇2R4 H CVb) These intermediates were directly converted into compounds of formula (I c) without separation. For example, Mitchell's condyle of formula (I) is known or can be prepared by conventional methods; some of them are commercially available. More to be determined, the paper of the compound of formula (H) has once again been used in the general home-made standard (CN'S) A.1 specification (210 X 297 g; Λ () 212801 V. Description of the invention (s) : A) propynoic acid ester; b) a-haloacrylate (obtained by the addition reaction of acrylic acid ester and halogen, obtained by dehydrohalogenation). For example, the 1,4-dihydro ft pyridine of formula (I) is known in "087/00836 (12.02.1987), or they can be split according to the method described in the international patent application. The compound of formula (I) can be used in the form of racemate and pure para-isomer. The useful cleavage method for the pure paraisomer of the compound of formula U) involves optical analysis of the isothiourea a formed with the optically active acid according to the method described in EP90102951.2 (15.02, 1990). Hexahydrogen as in formula (IV) is described in W087 / 01706 (26.03, 1987). The compounds of the present invention have been found to be effective in preventing and / or reducing excessive responsiveness of the respiratory tract and in treating inflammation associated with acute and subchronic inflammation of bronchial mucosa. The responsiveness of the bronchial encounter is a symptom of bedlessness of gas, which is usually doubled by the abnormal potential contraction and sensitivity of the bronchial mucosa. Bronchial fluency is delayed, and / or mildew is induced by external irritants such as inhalation of tobacco races, dirt, allergens, and endocrine secretions, which can cause an acute gas crisis. The status of excessive anti-plaque printing of the bronchus by the β-Consumer Cooperative Society of the Ministry of Economic Affairs of the Ministry of Economic Affairs can be simulated by experimental chess. It includes the infusion of PAF (600ju g / JL) into a male guinea pig with a human weight of 400 ~ 450g. He was kept under artificial anesthesia and under anesthesia of urethane and pancuroniu bromide. PAF, which is one of the most important media in the course of airway inflammation, causes an encounter response to various special substances (bronchoconstriction) after 1 hour of infusion. The activity of the compound of the present invention in the above-mentioned _experimental chess pattern is used to induce PAF paper size a with H3S Home Press Standard (CNS) f.1 regulation (210 X 297 public goods) _

0 V 0 V A6 B60 V 0 V A6 B6

212S0I 五、發明説明(9 ) 生之過度反應性之預防力表示,該過度反應性藉測量肺吸 入壓之增加度而得知(肺吸入S依照Naun. Schmied.212S0I V. Description of the invention (9) The preventive power of over-reactivity is said to be known by measuring the increase in lung inspiratory pressure (pulmonary inhalation S according to Naun. Schmied.

Arch. E x p e r . Pathol . Pharmacol. 19 1, 7 1, 1 970中,Arch. E x p e r. Pathol. Pharmacol. 19 1, 7 1, 1 970,

Konzett及Rossler所述之改良步驟測定)。 在PAF投藥前10分鐘投與2-50// g/kg之本發明化合物顯 示一持缠至少4〜6小時之保護作用.造成PAF誘發之過度 反慝降低。該藥理作用視劑量而定。 本發明之一些代表性化合物在PAF誘生之過度反應忒驗 中之活性被示於下表1中。 (請先閲璜背面之注意事項再填寫本頁) 化合物 表 天竺E醴内PAF誘生之過度反應 劑量(m g / k g ),十二指腸 内注射 降低% 丨裝, 訂· 經濟部中央標準局3工消費合作社印- 30 9 2 30 3 4 % 30 4 5 % 30 29 % 驗模型測試, 即致敏天竺鼠之 e t a 1 . , A .-a .Rev. Respir. 1 3 7 ;( 1 9 8 8 ); 5 8 - 5 7 7 )。後期反應之待if!為在對卵 實施例1 實施例2 -化合物1 賁施例2 -化合物2 實施例2 -化合物3 D ί 夂紙怅尺Λ連》1中as家棵準(CNS)窄4 «格(210 X 37公兑) 11 洚正— 21280i A6 Ιί _B6_ 五、發明説明(9&gt;) 白蛋白氣霧劑敏感化之天竺鼠髏内支氣管肺泡灌洗液 (BAL)中之_伊紅性白血球增加。本發明化合物在降低 BAL中嚙伊红性白血球之數目(於以卵白蛋白激起反應後72 小時測定)上有效。本發明之一代表性化合物在該試驗中 之活性被示於下表2中。 _2_ 卵白蛋白敏感化天竺鼠之後期反應 化合物 劑量U g / k g ) , 口服 嚙伊红性白血球浸潤 __ _ 之抑制%_ 實施例1 7 5 5 0 % 由上述顯示可知,本發明化合物可用於治療人類之氣喘 及^呼吸道之阻塞疾病,以及治療發炎性炎症。在所期望治 療用途中,本發明化合物可以藥學組成物之形式被投藥, 其可用賦形劑及習知技術製成,例如,雷明頓藥物科學手 冊(Mack出版公司,紐約,美國,第17版,1985年)中所述 適合供肌肉、靜脈、口服、噴霧及直腸方法投藥之劑型。 每曰劑量將因多種因素而定,例如疾病之駸重度及病人 之情況:對重70kg病人而言,式(I )化合物之劑量通常為 1〜50mg ,每日投藥一次或數次3 製備例1 表纸張尺度過用中围國家浮準(CNS&gt;田4規格(210 X ?97 乂兮)t 1 (Λ (請先閲讀背面之注意事項再填寫本頁) .裝. .ΤΓ. —線. 經濟部申央標準局S工消費合作社印«. Λ 6 B6 2l2B〇i 五、發明説明(10 ) (請先閲讀背面之注悉卞項再塡寫本頁) 在S-[(6-甲基-5-甲氣羰基-3-乙氣羰基-4-(3-硝基苯基 )-1,4-二氫吡啶-2-基)甲基]異碕脲氰化物(20g)懸浮於 MeOH(200ffl儿)之懸浮液中,於惰性氣體氛團、室溫及攪拌 下,順序加入丙酸甲酯(4.2bJL)及NaOH水溶液(35S:, 10.8 JL)。試薄I完全溶解後,形成結晶性沈澱,加入D M F ( 4 0 文)使該沈澱再溶解。谢绩再攪拌12小時,於此期間形成 第二次沈澱,將該沈澱遇濾,得到14.6g 2-(3-(5 -甲基-6 -甲氣羰基-7-(3-硝基苯基)-8-乙氣羰基)[3H, 7H]-曛唑 并[3 , 4 - a ]吡啶基)乙酸甲酯,b . p · 1 5 8 - 1 6 0它。 製備例2 於強烈攪拌下,將1升磺酸氫納跑和水溶液滴入50g(7R) -S-[(6-甲基-5-甲氣羰基-3-乙氧羰基-4-(3-硝基苯基)-1 ,4-二氫ttt啶-2-基)甲基]異碕脲-D-(—)-苯乙酵酸鹽懸浮 於1升AcOEt之懸浮液中。於添加終結時,移除水相,將有 機相經碱酸銷乾燥並於減壓下蒸除溶劑(溫度保持在40T 以下)。 經濟部中央標準局員工消费合作社印製 將殘留之(7R)-S-[(6-甲基-5-甲氣羰基-3-乙氣羰基-4-(3-硝基苯基)-1,4-二氫ttt啶-2-基)甲基異硫酵腺(37g)溶 於150儿甲酵中,並於機械攪拌及惟性氣黼氛圔下迅速加 入9·义丙炔酸甲酯,之後立即加入35XHaOH水溶液(11.3 义)。産物之沈濺幾乎立即發生。15分鐘後,在反應混合 物中加入37X鹽酸使其呈酸性pH值,然後將結晶固鼸濾出 及乾燥,得到40.2g(7R)-3-[(6 -甲基-5-甲氣羰基-3 -乙氣 羰基- 4-(3-硝基苯基)-1,4-二氫吡«-2-基)甲《«基]丙烯 衣纸張尺及通用中®因家桴芈(CNS)甲悅珞(210 X 297公兌) - 12 Λ6 2128G, 五'發明説明(u) (*-''''^閲._:'^而之注'4^-&quot;'!再码^本頁) 酸甲酯。 於攪拌及惰性氣體氛圓下,將12.801义1,3-二氮雜雙環 [5.4.0]十——7 -烯(DBU)加到 40.2g(7R)-3-[(6 -甲基-5-甲 氧羰基-3-乙氣羧基-4-(3-硝基苯基)-1,4-二氫吡啶-2-基 )甲骑基]丙烯酸甲酯溶於110Π文無水DMF中。曲鑛再攪拌 18小時,然後將反應混合物1用水/冰冷卻,並藉加入373;鹽 酸諏至酸性P Η值。結晶沈澱藉過濾分離,得到3 5 . 7 S ( 7 R )- 2- (3-(5-甲基-6-甲氣羰基-7-(3-¾基苯基)-8-乙氣羰基) -[3 Η , 7 Η ]曛唑并[3 , 4 - a ]吡啶基)乙酸甲酯.n . p . 1 2 6 - 1 2 8 Ό 〇 裂備例3 於攪拌下,將6.4g(7R)-2-(3-(5-甲基-6-甲氣羰基-7-( 1u. 3- 硝基苯基)-8-乙氣羰基)[3H, 7H]曛唑并〔3.4-a]吡啶基 )乙酸甲酯加到LiBr(3.8g)及硼氫化納(1.75g)fit浮於一縮 二乙二醇甲謎(10·文)之懸浮液中,該懸浮液先前被保持 在室溫下歴30分鐘。將反應混合物加熱至50Ό歴1小時, 經濟部中央標準局貝工消費合作社印v,代(Measured by the improved procedure described by Konzett and Rossler). Administration of 2-50 // g / kg of the compound of the present invention 10 minutes before PAF administration shows a protective effect of holding for at least 4 to 6 hours. This causes PAF-induced excessive anti-inverse reduction. The pharmacological effect depends on the dose. The activity of some representative compounds of the present invention in the PAF-induced overreaction assay is shown in Table 1 below. (Please read the precautions on the back of the window before filling in this page) Compound Table Tianzhu E Liquor's PAF-induced over-reactive dose (mg / kg), duodenal injection reduced by %%. Consumer Cooperative Seal-30 9 2 30 3 4% 30 4 5% 30 29% model test, that is, eta 1., A .-a .Rev. Respir. 1 3 7; (1 9 8 8) ; 5 8-5 7 7). The later reaction is waiting if! Is in the egg Example 1 Example 2-Compound 1 Ben Shi Example 2-Compound 2 Example 2-Compound 3 D ί 夂 纸 怅 尺 连连》 1 as a family standard (CNS) Narrow 4 «Grid (210 X 37)) 11 Huanzheng — 21280i A6 Ιί _B6_ V. Description of the invention (9>) In albumin aerosol sensitized guinea pig bronchoalveolar lavage fluid (BAL) Increased red blood cells. The compound of the present invention is effective in reducing the number of inosine leukocytes in BAL (measured 72 hours after evoked response with ovalbumin). The activity of a representative compound of the present invention in this test is shown in Table 2 below. _2_ Ovalbumin-sensitized guinea pig post-reactive compound dose U g / kg), Oral infiltration of eosinotic leukocytes __ _ Inhibition% _ Example 1 7 5 5 0% From the above display, it can be seen that the compounds of the present invention can be used for treatment Asthma in humans and obstructive diseases of the respiratory tract, as well as treatment of inflammatory inflammation. In the desired therapeutic use, the compound of the present invention can be administered in the form of a pharmaceutical composition, which can be prepared with excipients and conventional techniques, for example, Remington Pharmaceutical Science Handbook (Mack Publishing Company, New York, USA, 17th Edition , 1985) suitable for intramuscular, intravenous, oral, spray and rectal dosage forms. The daily dose will depend on various factors, such as the severity of the disease and the condition of the patient: for a patient weighing 70 kg, the dose of the compound of formula (I) is usually 1 to 50 mg, administered once or several times a day. 1 The paper size is used in the Zhongwei National Float Standard (CNS> Tian 4 specifications (210 X? 97 佂 兮) t 1 (Λ (please read the precautions on the back before filling out this page). Install. .ΤΓ. — Line. Printed by S Industry and Consumer Cooperatives of Shenyang Bureau of Standards, Ministry of Economics «. Λ 6 B6 2l2B〇i V. Description of invention (10) (Please read the note on the back first and then write this page). -Methyl-5-methylcarbonyl-3-ethylcarbonyl-4- (3-nitrophenyl) -1,4-dihydropyridin-2-yl) methyl] isocarbazide cyanide (20g) Suspend in MeOH (200ffl) suspension, under inert gas atmosphere, room temperature and stirring, add methyl propionate (4.2bJL) and aqueous NaOH solution (35S :, 10.8 JL). Test thin I completely dissolved After that, a crystalline precipitate was formed, and DMF (40%) was added to re-dissolve the precipitate. Xie Ji stirred for another 12 hours, during which a second precipitate was formed, which was filtered to obtain 14.6g of 2- (3- (5 -methyl-6- Methane carbonyl-7- (3-nitrophenyl) -8-ethane carbonyl) [3H, 7H] -benzozo [3, 4-a] pyridyl) methyl acetate, b. P · 1 5 8-1 6 0. Preparation Example 2 Under vigorous stirring, 1 liter of hydrogen sulfonate sodium run and aqueous solution were dropped into 50 g of (7R) -S-[(6-methyl-5-methanecarbonyl-3-ethyl Oxycarbonyl-4- (3-nitrophenyl) -1,4-dihydrottt-pyridin-2-yl) methyl] isoparaben-D-(—)-phenylacetate suspended in 1 liter of AcOEt In the suspension, at the end of the addition, remove the aqueous phase, dry the organic phase through the sale of alkali acid and evaporate the solvent under reduced pressure (the temperature is kept below 40T). Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs Residual (7R) -S-[(6-Methyl-5-methylcarbonyl-3-ethylcarbonyl-4- (3-nitrophenyl) -1,4-dihydrottt-pyridin-2-yl ) Methyl isothioacid gland (37g) is dissolved in 150g of methylenzyme, and methyl 9-propionate is added rapidly under mechanical agitation and unique atmosphere, followed by 35XHaOH aqueous solution immediately (11.3 meaning) The splashing of the product occurred almost immediately. After 15 minutes, 37X hydrochloric acid was added to the reaction mixture to make it acidic pH, and then the crystalline solid was filtered out and After drying, 40.2g (7R) -3-[(6-methyl-5-methylcarbonyl-3-ethylethanecarbonyl-4- (3-nitrophenyl) -1,4-dihydropyridine «- 2-base) A "« base] acrylic coat paper ruler and general-purpose medium ® Yinjiahuan (CNS) Jiayue Luo (210 X 297 public exchange)-12 Λ6 2128G, five 'invention description (u) (*- '' '' ^ Read ._: '^ And the note' 4 ^-&quot; '! Recode ^ this page) Methyl acid ester. Under stirring and inert gas atmosphere, add 12.801 1,3-diazabicyclo [5.4.0] deca- 7-ene (DBU) to 40.2g (7R) -3-[(6-methyl -5-Methoxycarbonyl-3-ethyl gas carboxy-4- (3-nitrophenyl) -1,4-dihydropyridin-2-yl) methanyl] methyl acrylate dissolved in 110ml of anhydrous DMF . The koji ore was stirred for another 18 hours, and then the reaction mixture 1 was cooled with water / ice, and 373; hydrochloric acid was added to the acidic pH value. The crystal precipitation is separated by filtration to obtain 35.7 S (7R) -2- (3- (5-methyl-6-methylcarbonyl-7- (3-¾ylphenyl) -8-ethanecarbonyl )-[3 Η, 7 Η] thiazolo [3, 4-a] pyridyl) methyl acetate. N. P. 1 2 6-1 2 8 Ό 〇 Split Example 3 Under stirring, 6.4g (7R) -2- (3- (5-Methyl-6-methoxycarbonyl-7- (1u. 3-nitrophenyl) -8-ethoxycarbonyl) [3H, 7H] benzozo [3.4 -a] pyridyl) methyl acetate was added to LiBr (3.8g) and sodium borohydride (1.75g) fit floated in a suspension of diethylene glycol methyl alcohol (10 · Wen), the suspension was previously Keep at room temperature for 30 minutes. Heat the reaction mixture to 50 ° C for 1 hour, printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs.

然後將其倒人水中並以1N鹽酸酸化。用AcOEt(3xl5·!) 荦取後,將合併之有機举取液用水(5X20BJI)反S洗滌, 經硫酸鈉乾燥及於減壓下蒸除溶劑,得到4.8g(7R)-2-(3-(5-甲基-6-甲氧羰基-7-(3-硝基苯基)-8-(乙氧羰基)[3H ,7 Η ] &gt;«唑并[3 , 4 - a ]吡啶基)-乙酵, . P . 5 8 - 6 2 ”, [ a ] D =51.9° (C= 0.21,溶於 EtOH)。 製锴例4 按照製備例2及3所述之方法,製備下列2-([3H, 7Η]·« 木纸張又茂遇用中ΒΚ家作苹(CN—S)甲.1规恪(210 X 297公贷) 13 2128C#! 經濟部中央標準局員工消費合作社印?代 五、發明説明(12) 唑并[3,4-a]吡啶-3-基)乙醇: 5-甲基-6-甲氣羰基-7-(3-氛苯基)-8-乙氣羰基, 5-甲基-6-甲氣羰基-7-琿己基-8-乙氧激基, 5-甲基-6-烯丙氣羧基-7-(3-硝基苯基)-8-乙氣羰基, 5-甲基-6-烯丙氣羰基- 7-(3-氯苯基)-8-乙氣羰基, 5-甲基-6-烯丙氣羰基-7-琛己基-8-乙氣1羰基。 實施例1 於S拌及惰性縈氣下,將1.74g硫羰二咪唑加到3.5g(7R )-2-(3-(5-甲基-6-甲氧欺基- 7-(3-硝基苯基)-8-乙氧羰 基)[3H, 7H]曛唑并[3,4-a]吡啶)乙醇溶於20b文無水THF 之溶液中。5小時後,將H-[3,6-貳(二乙胺基)吡啶-2-基] 六氬1ft唞(2.65g)溶於15nJLTHF之溶液逐滴加到反應混合 物中,於室溫下攪拌1小時以上,然後在反應混合物中加 入701»义水並用AcOEt(3x 20πι义)反覆萃取。將合併之有機 萃取液用水(3X10义)洗滌,經硫酸納乾燥及於減壓下蒸 去溶劑。殘餘物(6. 7g)»矽凝謬層析法(20 0 g|S化矽;溶 離劑:二氛甲烷/甲酵98/2)純化,得到4.3g(7R)-H-(3,6-貳(二乙胺)tft啶-2-基)-Ν’- (2-(3-(5-甲基-6-甲氧羰基-7 -(3-硝基苯基)-8-乙氣羰基)[3H, 7H]««唑并[3,4-a]吡啶 P 基)乙氣硫羰基)六氳啪唞· n . p ·碕酸鹽1 6 9 - 1 7 11: , [ oc ] D = + 4.4° (C=0.2,在乙酵中)。 實施例2 按照實施例1所述的步驟,製備下列(([3H, 7H]噻唑并[ 3,4-a]tft啶基)乙氧碕羰基)六氫吡唞; (諳先閱冶背而之注-事項再塡寫本頁) 本纸張尺度迖用中as家拃準(CNS)甲J规格(210 X 297公译) 14 21280. :\6 B6 五、發明説明(13 ) (7R) -N- (2 ,6-贰(吡咯啶 -1-基)哦淀-4- 基)-Η ,-(2- (3 -(5- 甲基-6-甲 氣羰基-7- (3- 硝基苯 基)-8-乙氣羰 基).m. p ., 硫酸鹽,1 6 2 - 1 6 5 t:, (4 , 6-贰 (吡咯啶-1-基 )-1,3, 5 -三哄- 2-基) -Η,- (2- (3-( 5-甲基-6- 甲氣羰基-7- (3-硝基 苯基)-8 -乙氣 羰基 1H NMR (200 MHz) S 1.26 (t,3H), 1.95 (m,8H), 2.34 (m,2H), 2.59 (s,3H), 3 .55 (m,14H), 3.67 (s,3H), 3.85 (m,2H), 4.14 (m,4H), 4.2 (d,lH), 4.65 (d,lH); 5.18 (s,lH), 5.5 (m,lH); 7.41 (t ,ΙΗ), 7.6 (d;lH), 1 3.05 (m,2H), Η- (2,6-贰 (吡咯啶-卜基 )哺啶- 4 -基)-N ,-(2- (3- (5-甲 基- (請先閲汸背面之注意事項再填寫本頁) 經濟部中央標準局R工消費合作社印製 6-甲氣羰基-7-(3-氯苯基)-8-乙氣羰基, 1H NMR (200 MHz) S 1.25 (t,3H); 1.93 (m,8H), 2.35 (m,2H), 2.6 (s,3H), 3.55 (m,14H), 3.67 (s,3H), 3.85 (m,2H), 4.15 (m,4H), 4.2 (d,lH), 4.65 (d,lH), 4.87 (s,iH), 5.19 (S,1H), 5.51 7.21 (m,4H), 1&lt;-(3,6-贰(二乙胺基)吡啶-2-基)-1&lt;’-(2-(3-(5-甲基-6- 甲氧羰基-7-(3-氛苯基)-8-乙氣羰基), 1H NMR (200 MHz) 6 0.97 1.1 (t,6H), 1.25 (t,3H), 2.35 (m,2H), 2.6 (s,3H), 2.98 (q,4H), 3.53 (m;10H), 3.68 (s,3H), 3.84 (m,2H), 4.14 (m,4H), 4.22 (d,lH); 4.66 (d,lH); 5.17 (s,lH), 5.51 (m,lH), 6.07 (d,lH), 7.1 (d,lH), 7.22 (m,4H), N-(4,6-贰(ttt 咯啶-1-基)-1,3,5-三唞-2-基)-N,- (2-(3-( .本紙張尺Λϋ用中國0家桴準(CNS)甲4規格(210 X 297公:$ ) 15 B6 280 五、發明説明(14 ) 5-甲基-6-甲氣羰基-7-(3-氯苯基)-8-乙氣羰基), 1H NMR (200 MHz) &lt;5 1.25 (t,3H), 1.93 (m,8H), 2.36 (m,2H), 2.59 (s,3H), 3.53 (ra;14H), 3.65 (s,3H) , 3.85 (ra,2H), 4.13 (m,4H) , 4.22 (d,lH), 4.67 (d,lH), 5.17 (s,lH), 5·52 (m,lH), 7.21 (m,4H), (2, 6-贰 (吡咯啶-卜基 )嘧啶 -4 -基,)-N · - (2 - (3 - (5--甲 基- 甲氣羰基 丨-7-環己基-8 -乙氧 羰基), lh NMR (200 MHz) 8 〇.' 98 (m,6H), 1.25 (t,3H), 1.49 (m,5H), 1,94 (m,8H), 2.35 (m,2H), 2.6 (s,3H), 3.54 (m,14H), 3.68 (s,lH), 3.85 (m,2H), 3.91 (d,lH); 4.13 (m,4H), 4.19 (d,lH), 4.64 (d,lH), 5.87 (s,lH), 5.51 (m,1H), (3 , 6-贰 (二乙 胺基)吡啶-2- 基)-N ’- (2- (3- (5-甲基 -6- 甲«羰基-7-琛己基-8-乙«羰基), (請先閲冶背而之注-莽^再塡寫本頁) 經濟部中央標準局貝工消費合作社印製 丄 H NMR (200 MHz) S 0.98 (m,12H), 1.05 (t,6H), 1.25 (t,3H), 1.51 (m,5H), 2.35 (m,2H); 2.61 (s;3H), 2.98 (q,4H), 3.53 (m,10H), 3.66 (s,3H), 3.84 (m,2H), 3.91 (d,lH), 4.14 (m,4H), 4.22 (d,lH), 4.66 (d;lH); 5.51 6.06 (d,lH), 7 .1 (d, 1H), N - (4 · 6 - 贰(tt咯啶-1- m )-i ,3,5-三唞-2-基)-N,- (2-(3 5-甲基- 6-甲彳 氧羰基-7 -琛己 基-8-乙氧羰基 ), NMR (200 MHz) 6 1.01 (m,6H), 1.25 (t,3H), 1.4 9 (m,5,H), 1.94 (m,8H), 2 .35 (m,2H), 2.6 (s,3H), 3.53 (m,14H), 3 .65 i (s,3H), 3.84 (m,2H), 3.91 (d,!H), 4.13 (m,4H), 4,19 (d,lH), 4 .64 (d,lH), 5.52 衣纸张又度適用中國國家標準(CNS)甲4規格(210 X 297公釐) 16 五、發明説明(15) Ν-(2, 6-贰(《t 咯啶-1-基)嘧啶-4-基)-Ν’- (2-(3-(5-甲基-6-烯丙氧羰基-7-(3-硝基苯基)-8-乙氧羰基), 1H NMR (200 MHz) ^ 1.25 (t,3H), 1.93 (m,8H), 2.31 (m,2H), 2.59 (s,3H), 3.55 (m,14H), 3.85 (m,2H); 4.13 (m,4H), 4.2 (d,lH), 4.61 (m,2H), 4.65 (d,lH), 4.84 (S,1H), 5.22 (m,3H), 5.49 5.9 (m,lH), 7.41 7.61 (d,lH), 8.05 (m,2H), N-(3,6-贰(二乙胺基)吡« - 2-基)-Ν·-(2-(3-(5-甲基-6-播丙氧羰基-7-(3-硝基苯基)-8-乙氧羰基〉, (請先閲1?背而之注意事項#项寫本頁)( XH NMR (200 MHz) b 0.97 (t,6H), 1.04 (t,6H), 1.25 (t,3H), 2 !.33 (m,2H), 2.61 (s,3H), 2.98 (q,4H), 3.52 (m,10H), 3.84 (m,2H), 4.13 (m,4H), 4.21 (d,lH), 4.61 (m,2H), 4. 66 (d,lH), 5 .22 (m,3H) , 5. 49 5.9 6.06 (d,lH), 7.1 (d,lH), 7.42 (t,lH), 7.6 (d,lH), 8.05 (m,2H), «-(4,6-贰(1«:咯啶-1-基)-1,3,5-三唞-2-基)-^-(2-(3-( 裝- 訂_ 線 經濟部中央標準局貞工消费合作社印製 5_甲基_ 6-烯丙氧羰基 -7-(3 -硝基苯基 )-8- 乙氣羰基 ), 1H NMR (200 MHz) ^ 1.25 (t,3H), 1.94 (m,8H), 2.33 (m,2H), 2.59 (s,3H), 3 .53 (m,14H), 3.84 (m,2H), 4.14 (ra,4H), 4.19 (d,lH), 4.62 (m,2H), 4.64 (d,lH), 5.22 (m,3H), 5.49 (m,lH), 5-91 (m,lH), 7.42 7.61 (d,lH), i 3.05 (m,2H), N-(2,6-贰(ttt 咯啶-1-基)哺啶-4-基)-Ν·-(2-(3-(5-甲基- 本《張尺度逍用中國國家«準(CN5) T4規格(210x297公*) «I. 7. 20,OQ^k(U) 17 2i28〇i Λ 6 Β6 五、發明説明(16 )6-烯丙氣羰基~7-(3-氣苯基)-8-乙氣羰基), LH NMR (200 MHz) S 1.25 (t;3H), 1.93 (m,8H); 2.33 (m,2H), 2.6 (s,3H), 3.54 (m,14H) ; 3.83 (m,2H), 4.13 (γτ\,4Η), 4.2 (d,lH), 4.6 (m,2H), 4.65 (d,lH), 4.86 (S ,ΙΗ), 5.21 (m,3H), 5.48 (m,1H), 5.89 (m,1H), 7.21 (m ,4Η), N- (3 , 6 -1C (二 乙胺基 )吡啶-2 -基)- N,- (2-(3-(5- 甲基-6- 烯 丙氣 羰基-7 -(3-氛 苯基)-8 -乙氧 玻基), LH NMR ( 200 MHz) ^ i 0.96 (t,6H), 1.03 (t,6H), 1.25 (t,3H), 2 . 33 (m,2H), 2.58 (s,3H), 2.98 (q,4H), 3.51 (m,10H) ,3.83 (ra,2H), 4.13 (m,4H), 4.19 (d,lH), 4 .62 (m,2H), 4.64 (d,lH), 5.22 (m,3H), 5.48 (m,lH), 5.89 (m,lH), 6.06 (d,lH), 7.11 (d,lH), 7.23 (m,4H), H-(4,6-貳(ft 咯啶-卜基)-1,3,5-三唞-2-基)4'-(2-(3-( 5-甲基-6-烯丙氧羰基-7-(3-氰苯基)-8-乙氣羰基), (諳先閱^、背面之注念事項再塡寫本頁) 經濟部中央標準局員工消费合作社印製 ^-H NMR (200 MHz) δ 1.26 (t,3H), 1.93 (m,8H), 2.33 (nt,2H), 2.57 (s,3H), 3.53 (m,14H), 3.84 (m,2H); 4.14 (m,4H), 4.21 (d,lH), 4.62 (m,2H), 4.66 (d,lH), 5.23 (m;3H), 5.48 (m,lH), 5.88 (m,lH), 7.22 (m,4H), N- (2,6- 贰Oft咯啶-1- 基)哺啶-4-基)-ir - (2-(3-(5 -甲基 6-烯丙氣羰基 -7-琢己 基-8-乙氧羰基), 1H NMR (200 MHz) 5 0 .98 (m,6H); 1.26 (t,3H), 1.51 衣纸張又及迪用中家作芈(CNS)甲.1规丨各(210 X 297公坌) 18 BC 五、發明説明(17 ) (m,5H), 1.94 (m,8H), 2.33 (m,2H), 2.59 (S,1H), 3.53 (m,14H), 3.83 (m,2H), 3.91 (d,lH), 4.13 (ra,4H), 4.19 (d,lH), 4.61 (m,2H), 4.64 (d,1H), 4.86 (s;lH), 5.22 (m,2H), N- (3,6- 5.48 (m,1H), 5.88 (m,1H), 贰(二乙胺基)吡啶-2 -基)- '-(2- (3- (5-甲 基-6 烯丙氣羰基-7 -環己基 -8-乙 氣羰基), -'H NMR (200 MHz) 6&quot;: L.01 (m,12H), 1.05 (t,6H), 1.26 (t,3Η), 1.49 (m,5H), 2.33 (m,2H), 2:59 (s,3H), 2.97 (q,4H), 3.52 (m,10H), 3 .83 (m,2H), 3.9 (d,1H), 4.12 (m,4H), 4.2 (d,lH), 4.6 (m,2H), 4 . 65 (d,lH), 5.21 (m,2H), 5.48 (m,lH), 5 . 9 (m,1H), 6.06 (d,lH), 7.11 (-也問*;3背面之注念&quot;項再塡寫本頁) (d,1H), N - (4 ,6-¾ v Θ 症-1-基)-1 ,3,5- 三喵-2-基)-H '-(2- (3 5-甲 基-6-烯丙氣羰基-7-環 己基- 8-乙氧羰 基), 1H NMR (200 MHz) 6 0.98 (m,6H), 1.25 (t,3H), 1.49 (m,5H), 1.93 (m,8H), 2.33 (m,2H), 2.59 (S,3H), 3.55 (m,14H), 3.83 (m;2H), 3.89 (d,lH), 4.13 (m,4H), 4.19 (d,lH), 4.59 (m,2H), 4.64 (d,lH), 5.21 (m,2H), 5.48 5.87 . 實施例3 a)於攪拌及慊性氣《氛醑下,將0.25gl0XPd/C, 0.37g 甲酸銨及15ng三苯鰣加到lg N-[2,6 -贰(Ift咯啶-1-基)嘧 啶-4-基]-Ν’ [2-(3-(5-甲基-6-烯丙氣羰基-7-(3-硝基苯 基)-8-乙氧羰基)[3H, 7H]&gt;«唑并[3,4-a]ttt啶基)乙氣硫 羧基]六氫吡哄溶於“儿二聘烷之溶液中,然後將反應混 衣纸张又度適叫中家作準(CNS)甲‘1規格(2U&gt; X 297公牮) - 19 - -裝- 經·濟部中央標準局員工消费合作社印製 Λ() _R6_ 五、發明説明(18 ) (-先&quot;-背而之注念?項再塡寫本頁) 合物回流6小時。之後,將反應混合物經矽藻土過濾,用 AcOEt(10uJL)稀釋並用水(3x5nJl)反覆洗滌。將生成之 有機相經硫酸銷乾燥及將溶劑於減壓下蒸發,以得到殘餘 物(0.9g),將該殘餘物藉氣化矽膠層析(30g氣化矽;溶離 劑:己烷/ AcOEt 6/4)而純化。得到0.8g H-l2,6-贰(吡咯 啶-卜基)哺啶-4-基]-Ν’- [2-(3-(5-ΐ基-6-羧基-7-(3-硝 基苯基)-8-乙氧羰基)[3H, 7H]曛唑并[3,4-a]吡啶基)乙 氣碕羰基]六氫吡唞。 b)於携拌及惰性氣體氛圍下,將0.135g羧基二咪唑加到 0.8g N-[2,6 -贰(«;咯啶-卜基)嘧啶-4 -基]-fT-[2-(3-(5-甲基-6 -羧基- 7- (3-¾基苯基)-3 -乙氧羰基)[3H, 7H]噻唑 并[3,4-a]吡啶基)乙氣硫羰基]六氫吡唞溶於5BJLTHF之溶 液中。3小時後,在反醮混合物中加入0.65nJl 2-(N-t«i咯 經濟部中央標準局員工消費合作社印*'*代 啶)乙胺並再繼缅攪拌5小時。然後將混合物用15n儿水稀 釋並用AcOEt(3X5iJl)萃取。將合併之有機荦取液用水洗 滌,經硫酸鈉乾燥及於減壓下蒸除溶劑。殘餘物(lg)«« 化矽凝膠層析(30g氣化矽;溶離劑:己烷/ AcOEt 8/2)而 純化,得到0.82g N-[2,6-贰(Ift咯啶-1-基)嘧啶-4-基]-N’-[2-(3-(5-甲基-6-(2-(N-ftfc 咯啶)乙胺羰基)-7-(3-硝 基苯基)-8-乙氧玻基)[3H, 7H]««唑并[3,4-a]吡啶基)乙 氧硫羰基]六氫吡唞, 1H NMR (200 MHz) b 1.25 (t,3H), 1.84 (m,4H), 1 • 95 (m,8H); 2.33 (m,2H), 2.59 (s,3H), 2.8 (m,6H); 3 -51 (m,16H), 3.84 (m,2H), 4.13 (m,4H), 4.19 (d,lH), 4 .64 (d,lH), 4.84 (S,1H), 5.21 (S,1H), 5.48 (m;1H), 7.2 (b,lH)7 7.41 (t,lH), 7.6 (d,lH), 8.03 (m,2H). 表纸張尺度適用中國0家標準(CNS)甲4規格(210 X 297公釐) 20It was then poured into water and acidified with 1N hydrochloric acid. After taking with AcOEt (3xl5 ·!), The combined organic extracts were washed with water (5X20BJI), dried over sodium sulfate and the solvent was distilled off under reduced pressure to obtain 4.8g (7R) -2- (3 -(5-Methyl-6-methoxycarbonyl-7- (3-nitrophenyl) -8- (ethoxycarbonyl) [3H, 7 Η] &gt; «Zolo [3, 4-a] pyridine Base)-ethyl yeast,. P. 5 8-6 2 ”, [a] D = 51.9 ° (C = 0.21, soluble in EtOH). Example 4 of preparation method According to the method described in Preparation Examples 2 and 3, prepare the following 2-([3H, 7Η] · «Wood paper and Mao Yuzhong BKK family Zuoping (CN—S) A.1 regulations (210 X 297 public loan) 13 2128C #! Printed by the employee consumer cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs ? Generation five, description of the invention (12) oxazolo [3,4-a] pyridin-3-yl) ethanol: 5-methyl-6-methyloxycarbonyl-7- (3-aminophenyl) -8-ethyl Gas carbonyl, 5-methyl-6-methyl gas carbonyl-7-ethylhexyl-8-ethoxykinyl, 5-methyl-6-allyl gas carboxy-7- (3-nitrophenyl) -8 -Ethoxycarbonyl, 5-methyl-6-allyloxycarbonyl-7- (3-chlorophenyl) -8-ethoxycarbonyl, 5-methyl-6-allyloxycarbonyl-7-chenhexyl- 8-ethane gas 1 carbonyl. Example 1 Under S inert inert gas, 1.74g thiocarbonyldiimidazole was added to 3.5g (7R) -2- (3- (5-methyl-6-methoxypyridyl-7- (3-nitrophenyl) -8-ethoxycarbonyl) [3H, 7H] benzozo [ 3,4-a] pyridine) ethanol was dissolved in a solution of 20b anhydrous THF. After 5 hours, H- [3,6-II (diethylamino) pyridin-2-yl] hexahydrogen 1ft (2.65 g) The solution dissolved in 15nJLTHF was added dropwise to the reaction mixture, stirred at room temperature for more than 1 hour, then 701 »water was added to the reaction mixture and extracted repeatedly with AcOEt (3x 20π 义). The combined organic extracts Wash with water (3X10), dry with sodium sulfate and evaporate the solvent under reduced pressure. Residue (6.7 g) »Silicon Condensation Chromatography (20 0 g | S silica); Dissolving agent: Dichloromethane / Formazan 98/2) purification, to obtain 4.3g (7R) -H- (3,6-two (diethylamine) tft pyridin-2-yl) -Ν'- (2- (3- (5-methyl -6-Methoxycarbonyl-7- (3-nitrophenyl) -8-ethoxycarbonyl) [3H, 7H] «« oxazolo [3,4-a] pyridine P-yl) ethoxythiocarbonyl) hexa鰲 唞 · n. P · Anoate 1 6 9-1 7 11:, [oc] D = + 4.4 ° (C = 0.2 in ethyl yeast). Example 2 Follow the steps described in Example 1 , Prepare the following (([3H, 7H] thiazolo [3,4-a] tf t-pyridinyl) ethoxylated carbonyl) hexahydropyridine; (read the notes before the smelting-matters and then write this page) This paper is used in the Chinese as standard (CNS) A J specifications (210 X 297 public translation) 14 21280.: \ 6 B6 V. Description of the invention (13) (7R) -N- (2,6-Second (pyrrolidin-1-yl) ohdian-4-yl) -Η,- (2- (3-(5-methyl-6-methylcarbonyl-7- (3-nitrophenyl) -8-ethanecarbonyl) .m.p., Sulfate, 1 6 2-1 6 5 t :, (4, 6-Two (pyrrolidin-1-yl) -1,3, 5 -trifluoro-2-yl) -Η,-(2- (3- (5-methyl-6- Methane carbonyl-7- (3-nitrophenyl) -8-ethane carbonyl 1H NMR (200 MHz) S 1.26 (t, 3H), 1.95 (m, 8H), 2.34 (m, 2H), 2.59 ( s, 3H), 3 .55 (m, 14H), 3.67 (s, 3H), 3.85 (m, 2H), 4.14 (m, 4H), 4.2 (d, lH), 4.65 (d, lH); 5.18 (s, lH), 5.5 (m, lH); 7.41 (t, ΙΗ), 7.6 (d; lH), 1 3.05 (m, 2H), Η- (2,6-II (pyrrolidinyl-butyl) Feeding-4-yl) -N,-(2- (3- (5-methyl- (please read the precautions on the back of 汸 before filling out this page) Printed by R Industry and Consumer Cooperatives, Central Bureau of Standards, Ministry of Economic Affairs 6- Methane carbonyl-7- (3-chlorophenyl) -8-ethane carbonyl 1H NMR (200 MHz) S 1.25 (t, 3H); 1.93 (m, 8H), 2.35 (m, 2H), 2.6 (s, 3H), 3.55 (m, 14H), 3.67 (s, 3H), 3.85 (m, 2H), 4.15 (m, 4H), 4.2 (d, lH), 4.65 (d, lH), 4.87 (s, iH), 5.19 (S, 1H), 5.51 7.21 (m, 4H), 1 &lt;-( 3,6-Two (diethylamino) pyridin-2-yl) -1 &lt; '-(2- (3- (5-methyl-6-methoxycarbonyl-7- (3-chlorobenzene Radical) -8-ethane gas carbonyl), 1H NMR (200 MHz) 6 0.97 1.1 (t, 6H), 1.25 (t, 3H), 2.35 (m, 2H), 2.6 (s, 3H), 2.98 (q, 4H), 3.53 (m; 10H), 3.68 (s, 3H), 3.84 (m, 2H), 4.14 (m, 4H), 4.22 (d, lH); 4.66 (d, lH); 5.17 (s, lH ), 5.51 (m, lH), 6.07 (d, lH), 7.1 (d, lH), 7.22 (m, 4H), N- (4,6-II (ttt pyrrolidin-1-yl) -1, 3,5-tris-2-yl) -N,-(2- (3- (. This paper ruler Λϋ uses the Chinese 0 Jiazheng (CNS) A 4 specifications (210 X 297 public: $) 15 B6 280 5. Description of the invention (14) 5-methyl-6-methyl gas carbonyl-7- (3-chlorophenyl) -8-ethane gas carbonyl), 1H NMR (200 MHz) &lt; 5 1.25 (t, 3H) , 1.93 (m, 8H), 2.36 (m, 2H), 2.59 (s, 3H), 3.53 (ra; 14H), 3.65 (s, 3H), 3.85 (ra, 2H), 4.13 (m, 4H), 4.22 (d, lH), 4.67 (d, lH), 5.17 (s, lH), 5.52 (m, lH), 7.21 (m, 4H), (2, 6- Two (pyrrolidinyl-pyridyl) pyrimidin-4-yl,)-N ·-(2-(3- (5-methyl-methylcarbonylcarbonyl-7-cyclohexyl-8-ethoxycarbonyl), lh NMR (200 MHz) 8 〇. '98 (m, 6H), 1.25 (t, 3H), 1.49 (m, 5H), 1,94 (m, 8H), 2.35 (m, 2H), 2.6 (s, 3H), 3.54 (m, 14H), 3.68 (s, lH), 3.85 (m, 2H), 3.91 (d, lH); 4.13 (m, 4H), 4.19 (d, lH), 4.64 (d, lH ), 5.87 (s, lH), 5.51 (m, 1H), (3, 6-Two (diethylamino) pyridin-2-yl) -N '-(2- (3- (5-methyl- 6- A «carbonyl-7-Chenhexyl-8-B« carbonyl), (please read the back-end notes first-mand ^ and then write this page) Printed by the Ministry of Economic Affairs Bureau of Central Standards Bureau Pongong Consumer Cooperative H NMR (200 MHz) S 0.98 (m, 12H), 1.05 (t, 6H), 1.25 (t, 3H), 1.51 (m, 5H), 2.35 (m, 2H); 2.61 (s; 3H), 2.98 (q , 4H), 3.53 (m, 10H), 3.66 (s, 3H), 3.84 (m, 2H), 3.91 (d, lH), 4.14 (m, 4H), 4.22 (d, lH), 4.66 (d; lH); 5.51 6.06 (d, lH), 7.1 (d, 1H), N-(4.6 · 2- (ttpyridine-1-m) -i, 3,5-tris-2-yl ) -N,-(2- (3 5-methyl-6-methyloxycarbonyl-7-chenhexyl-8-ethoxycarbonyl), NMR (200 MHz) 6 1.01 (m, 6H), 1.25 (t , 3H), 1.4 9 (m, 5, H), 1.94 (m, 8H), 2. .35 (m, 2H), 2.6 (s, 3H), 3.53 (m, 14H), 3.65 i (s, 3H), 3.84 (m, 2H), 3.91 (d,! H), 4.13 (m, 4H), 4,19 (d, lH), 4.64 (d, lH), 5.52 Clothing paper is again applicable to Chinese national standards ( CNS) A 4 specifications (210 X 297 mm) 16 V. Description of the invention (15) Ν- (2, 6-Two ("t pyrrolidin-1-yl) pyrimidin-4-yl) -Ν'- (2 -(3- (5-methyl-6-allyloxycarbonyl-7- (3-nitrophenyl) -8-ethoxycarbonyl), 1H NMR (200 MHz) ^ 1.25 (t, 3H), 1.93 (m, 8H), 2.31 (m, 2H), 2.59 (s, 3H), 3.55 (m, 14H), 3.85 (m, 2H); 4.13 (m, 4H), 4.2 (d, lH), 4.61 ( m, 2H), 4.65 (d, lH), 4.84 (S, 1H), 5.22 (m, 3H), 5.49 5.9 (m, lH), 7.41 7.61 (d, lH), 8.05 (m, 2H), N -(3,6-Two (diethylamino) pyridine «-2-yl) -Ν ·-(2- (3- (5-methyl-6-propanoxycarbonyl-7- (3-nitro Phenyl) -8-ethoxycarbonyl>, (please read 1? Back to the notes # item write this page) (XH NMR (200 MHz) b 0.97 (t, 6H), 1.04 (t, 6H), 1.25 (t, 3H), 2! .33 (m, 2H), 2.61 (s, 3H), 2.98 (q, 4H), 3.52 (m, 10H), 3.84 (m, 2H), 4.13 (m, 4H ), 4.21 (d, lH), 4.61 (m, 2H), 4. 66 (d, lH), 5.22 (m, 3H), 5. 49 5.9 6.06 (d, lH), 7.1 (d, lH), 7.42 (t, lH), 7.6 (d, lH), 8.05 (m, 2H), «-(4,6-Two (1«: pyrridine -1-yl) -1,3,5-tris-2-yl)-^-(2- (3- (Packing-booking_ Printed by the Ministry of Economic Affairs, Central Standards Bureau, Zhengong Consumer Cooperative 5_Methyl_ 6-allyloxycarbonyl-7- (3-nitrophenyl) -8-ethoxycarbonyl), 1H NMR (200 MHz) ^ 1.25 (t, 3H), 1.94 (m, 8H), 2.33 (m, 2H), 2.59 (s, 3H), 3.53 (m, 14H), 3.84 (m, 2H), 4.14 (ra, 4H), 4.19 (d, lH), 4.62 (m, 2H), 4.64 (d , lH), 5.22 (m, 3H), 5.49 (m, lH), 5-91 (m, lH), 7.42 7.61 (d, lH), i 3.05 (m, 2H), N- (2,6- Two (ttt pyrrolidin-1-yl) piperidin-4-yl) -Ν ·-(2- (3- (5-methyl-this "Zhang scales use Chinese national standards" (CN5) T4 specifications (210x297 Male *) «I. 7. 20, OQ ^ k (U) 17 2i28〇i Λ 6 Β6 V. Description of the invention (16) 6-allyl gas carbonyl ~ 7- (3-gas phenyl) -8-B Gas carbonyl), LH NMR (200 MHz) S 1.25 (t; 3H), 1.93 (m, 8H); 2.33 (m, 2H), 2.6 (s, 3H), 3.54 (m, 14H); 3.83 (m, 2H), 4.13 (γτ \, 4Η), 4.2 (d, lH), 4.6 (m, 2H), 4.65 (d, lH), 4.86 (S, ΙΗ), 5.21 (m, 3H), 5.48 (m, 1H), 5.89 (m, 1H), 7.21 (m, 4Η), N- (3, 6- 1C (diethylamino) pyridin-2-yl) -N,-(2- (3- (5-methyl-6-allyl gas carbonyl-7- (3-aminophenyl) -8-ethoxy Glassy), LH NMR (200 MHz) ^ i 0.96 (t, 6H), 1.03 (t, 6H), 1.25 (t, 3H), 2.33 (m, 2H), 2.58 (s, 3H), 2.98 (q, 4H), 3.51 (m, 10H), 3.83 (ra, 2H), 4.13 (m, 4H), 4.19 (d, lH), 4.62 (m, 2H), 4.64 (d, lH), 5.22 (m, 3H), 5.48 (m, lH), 5.89 (m, lH), 6.06 (d, lH), 7.11 (d, lH), 7.23 (m, 4H), H- (4,6-Two (Ft pyrrolidine-butyl) -1,3,5-tris-2-yl) 4 '-(2- (3- (5-methyl-6-allyloxycarbonyl-7- (3-cyano Phenyl) -8-ethoxycarbonyl), (first read ^, note on the back and then write this page) Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs ^ -H NMR (200 MHz) δ 1.26 (t , 3H), 1.93 (m, 8H), 2.33 (nt, 2H), 2.57 (s, 3H), 3.53 (m, 14H), 3.84 (m, 2H); 4.14 (m, 4H), 4.21 (d, lH), 4.62 (m, 2H), 4.66 (d, lH), 5.23 (m; 3H), 5.48 (m, lH), 5.88 (m, lH), 7.22 (m, 4H), N- (2, 6-Two Oft Pyridin-1-yl) Rhinidine-4-yl) -ir-(2- (3- (5- (6-Methyl 6-allyl carbonyl-7-cuthexyl-8-ethoxycarbonyl) , 1H NMR (200 MHz) 5 0.98 ( m, 6H); 1.26 (t, 3H), 1.51 clothing and paper, and Di Zhongzhong Zuojia (CNS) A.1 rules and regulations (210 X 297 gong) 18 BC V. Description of the invention (17) ( m, 5H), 1.94 (m, 8H), 2.33 (m, 2H), 2.59 (S, 1H), 3.53 (m, 14H), 3.83 (m, 2H), 3.91 (d, lH), 4.13 (ra , 4H), 4.19 (d, lH), 4.61 (m, 2H), 4.64 (d, 1H), 4.86 (s; lH), 5.22 (m, 2H), N- (3,6- 5.48 (m, 1H), 5.88 (m, 1H), II (diethylamino) pyridin-2-yl) -'- (2- (3- (5-methyl-6allylcarbonylcarbonyl-7-cyclohexyl-8 -Ethane carbonyl), -'H NMR (200 MHz) 6 &quot;: L.01 (m, 12H), 1.05 (t, 6H), 1.26 (t, 3Η), 1.49 (m, 5H), 2.33 (m , 2H), 2:59 (s, 3H), 2.97 (q, 4H), 3.52 (m, 10H), 3.83 (m, 2H), 3.9 (d, 1H), 4.12 (m, 4H), 4.2 (d, lH), 4.6 (m, 2H), 4.65 (d, lH), 5.21 (m, 2H), 5.48 (m, lH), 5.9 (m, 1H), 6.06 (d, lH), 7.11 (-also ask *; 3 note on the back &quot; item then write this page) (d, 1H), N-(4,6-¾ v Θ syndrome-1-yl) -1,3 , 5-trimethyl-2-yl) -H '-(2- (3 5-methyl-6-allylcarbonyl-7-cyclohexyl-8-ethoxycarbonyl), 1H NMR (200 MHz) 6 0.98 (m, 6H), 1.25 (t, 3H), 1.49 (m, 5H), 1.93 (m, 8H), 2. 33 (m, 2H), 2.59 (S, 3H), 3.55 (m, 14H), 3.83 (m; 2H), 3.89 (d, lH), 4.13 (m, 4H), 4.19 (d, lH), 4.59 (m, 2H), 4.64 (d, lH), 5.21 (m, 2H), 5.48 5.87. Example 3 a) Under stirring and vigorous gas "atmosphere", 0.25gl0XPd / C, 0.37g ammonium formate and 15ng triphenylshaven was added to lg N- [2,6-di (Ift pyridin-1-yl) pyrimidin-4-yl] -Ν '[2- (3- (5-methyl-6-allyl gas Carbonyl-7- (3-nitrophenyl) -8-ethoxycarbonyl) [3H, 7H] &gt; «oxazolo [3,4-a] ttt pyridyl) ethyl gas thiocarboxy] hexahydropyridine In the solution of "Er Erban", then the reaction mixed paper is appropriately called Zhongjia Zuozheng (CNS) A'1 specification (2U> X 297 Gongzi)-19--installation-Central Standard of Economy and Economy Printed by the Bureau ’s Consumer Cooperatives Λ () _R6_ V. Description of the invention (18) (-first &quot; -Contrary? Xiang Zaicheng wrote this page) The compound was refluxed for 6 hours. After that, the reaction mixture was filtered through celite, diluted with AcOEt (10uJL) and washed repeatedly with water (3x5nJl). The resulting organic phase was dried over sulfuric acid and the solvent was evaporated under reduced pressure to obtain a residue (0.9g), which was chromatographed by vaporized silica gel (30g vaporized silica; dissolving agent: hexane / AcOEt 6/4). 0.8 g of H-l2,6-II (pyrrolidinyl-bromo) piperidin-4-yl] -Ν '-[2- (3- (5-lyl-6-carboxy-7- (3-nitro Phenyl) -8-ethoxycarbonyl) [3H, 7H] thiazolo [3,4-a] pyridyl) acetylene carbonyl] hexahydropyridine. b) Add 0.135g of carboxydiimidazole to 0.8g of N- [2,6-Ⅱ («; pyridine-butyl) pyrimidin-4-yl] -fT- [2- (3- (5-Methyl-6-carboxy-7- (3-¾ylphenyl) -3-ethoxycarbonyl) [3H, 7H] thiazolo [3,4-a] pyridyl) ethanesulfur Carbonyl] hexahydropyridine dissolved in 5BJLTHF solution. After 3 hours, add 0.65nJl 2- (N-t «i) printed by the Ministry of Economic Affairs, Central Bureau of Standards, Employee and Consumer Cooperatives ****, and then stir in Myanmar for another 5 hours. The mixture was then diluted with 15n water and extracted with AcOEt (3X5iJl). The combined organic extracts were washed with water, dried over sodium sulfate and the solvent was distilled off under reduced pressure. The residue (lg) «« silica gel chromatography (30g vaporized silica; dissolving agent: hexane / AcOEt 8/2) and purified, to obtain 0.82g N- [2,6-II (Ift pyridine-1 -Yl) pyrimidin-4-yl] -N '-[2- (3- (5-methyl-6- (2- (N-ftfc pyrrolidine) ethylaminecarbonyl) -7- (3-nitrobenzene Group) -8-ethoxy glassy group) [3H, 7H] «« oxazolo [3,4-a] pyridyl) ethoxythiocarbonyl] hexahydropyridine, 1H NMR (200 MHz) b 1.25 (t, 3H), 1.84 (m, 4H), 1 • 95 (m, 8H); 2.33 (m, 2H), 2.59 (s, 3H), 2.8 (m, 6H); 3 -51 (m, 16H), 3.84 (m, 2H), 4.13 (m, 4H), 4.19 (d, lH), 4.64 (d, lH), 4.84 (S, 1H), 5.21 (S, 1H), 5.48 (m; 1H), 7.2 (b, lH) 7 7.41 (t, lH), 7.6 (d, lH), 8.03 (m, 2H). The table paper scale is applicable to 0 Chinese standards (CNS) A4 specifications (210 X 297 mm) 20

BfaBfa

aiaBQ 五、發明説明(19) 實施例4 按照實施例1所述之方法,自實施例2所述之(6-烯丙氧 羰基)[3H, 7H]曛唑并[3,4-a]吡啶,製得下列(6-(2-(N-吡咯啶基)乙胺羰基)[3H, 7H]曛唑并[3,4-a]吡啶基)乙氣 碕羰基)六氫吡唞: (諳先閲*;;ί背面之注意事項再塡寫本頁) 貳(二乙胺基)¾啶- 2-基) ,-(2- (3- (5-甲 基-7 三基)-8-乙氧羰 基), 1H NMR (200 0.98 (t,6H), 1.03 (t,6H), 1.26 (t,3H), 1.85 2.33 (m,2H), 2.59 (S,3H), 2.85 (m,10H), 3.51 3.83 (m,2H), 4 . 13 (m,4H), 4.19 (d,lH), 4.64 5.19 (s,lH), 5.5 (m,lH), 6.07 (d,lH), 7.11 7 . L8 (b,!H), 7.41 (t,lH), 7.6 (d,lH), 8.03 裝— 訂_ 經濟部中央標準局員工消费合作社印- (m,2H), 只-(4,6-貳(1»咯啶-:1-基)-:1,3,5-三唞-2-基)-«'-(2-(3-5-甲基-7-(3-硝基苯基)-8-乙氧羰基), 1« NMR (200 MHz) S 1.26 (t,3H), 1.84 (m,4H), 1.96 (m,8H), 2.33 (ra,2H), 2.58 (s,3H), 2.81 (πι,βΗ), 3.52 (rn,16H), 3.83 (m,2H), 4.11 (m,4H), 4.18 (d,lH), 4.63 (d,lH), 5.19 (S,1H), 5.5 7.15 (b,lH), 7.42 (t,lH), 7.59 (d,lH), 8.05 (m,2H), N-(2,6-貳(ttt 咯啶-1-基)喃啶-4-基)-N,- (2-(3-(5-甲基 本紙張尺度適用中阀S家作準(CNS)甲4规格(210 X 297公釐) 31 212601 五、發明説明(20) -7- (3-氯苯基 )-8-乙氣羧基 ), 1h NMR (200 MHz) S 1. 26 (t;3H), 1.84 (m,4H), 1.95 (m,8H), 2.35 (m,2H), 2.59 (s,3H), 2.82 (m,6H), 3.52 (m,16H); 3.83 (m,2H), 4.13 (m,4H), 4.19 (d,lH), 4.64 (d,lH), 4.86 (s,ΙΗ), 5.18 ( S,1H), 5.48 7.23 (m,5H), N-(3,6 - 贰(二 乙胺基)吡啶- 2-基)-N,- (2- (3- (5-甲 基-7- (3-氛苯 基)-8 -乙氣羰基), 1h NMR (200 MHz) 5 0.96 (t,6H) , 1.04 (t,6H)( 1.26 (t,3H), 1.83 (m,4H), 2.33 (m,2H), 2.59 (s,3H), 2.79 (m,6H), 2.99 (q,4H), 3.51 (m,12H), 3.83 (ra,2H), 4.13 (m,4H), 4.21 (d;1H), 4.66 (d,lH), 5.21 (s,1H), 5.48 (m,1H), 6:06 (d,!H), 7.11 (d;lH), 7.23 (m,5H), (請先閱汸背面之注念事項再塡寫本頁) i .装. 訂. 絰濟部中央標準局WK工消費合作社印製 1^-(4,6-武((11;格淀-1_基)_.1,3,5-三书-2-基)_^1’-(2-(3-( 5-甲基-7-(3-氛苯基)-8-乙氣羰基), MMR ( 200 MHz) S 1.25 (t,3H), 1.84 1.95 (m,8H), 2.33 (ra,2H), 2.59 (s,3H), 2.8 (m;6H); 3.5 (m;16H), 3.83 (m,2H), 4.15 (m,4H), 4.2 (d,lH), 4.65 (d,lH), 5.21 (S,1H), 5.5 (m,lH), 7.23 (m,5H), N-(2,6-¾ (¾ 咯啶-1-基)哺啶-4-基)-H,- (2-(3-(5-甲基 7-環己基-8-乙氧羰基), 本紙張又度適用中國國家標準(CNS)甲4規格(210 X 297公:$ ) 22 .線. Λ6 B6 2l2d〇^- 五、發明説明(21) , lR NMR ( 200 MHz) ^0.99 (m7 6H), 1,26 (t,3H), 1.51 (m ;5H); 1.84 (m,4H), 1.95 (m,8H), 2. 33 (m,2H), 2· 6 (s,3H), 2.81 (m,6H), 3.51 (m,16H), 3.83 (m,2H), 3.91 (d,lH), 4.13 (m,4H), 4.19 (d,1H), 4.64 (d,lH), 4.86 (S,1H), 5.5 7.2 (b,lH), H- (3 , 6-贰(二乙胺基)吡啶- 2-基)-N ’ _ (2 - (3 - (5 -甲 基-7 環己基-8-乙氣 羰基), * (請先閱讀背面之注意事項再塡寫本頁)aiaBQ 5. Description of the invention (19) Example 4 According to the method described in Example 1, the (6-allyloxycarbonyl) [3H, 7H] benzozo [3,4-a] described in Example 2 Pyridine, to prepare the following (6- (2- (N-pyrrolidinyl) ethylamine carbonyl) [3H, 7H] thiazolo [3,4-a] pyridyl) ethane gas carbonyl) hexahydropyridine: (Read first * ;; Note on the back then write this page) Two (diethylamino) ¾ pyridine-2-yl),-(2- (3- (5-methyl-7 triyl) -8-ethoxycarbonyl), 1H NMR (200 0.98 (t, 6H), 1.03 (t, 6H), 1.26 (t, 3H), 1.85 2.33 (m, 2H), 2.59 (S, 3H), 2.85 ( m, 10H), 3.51 3.83 (m, 2H), 4.13 (m, 4H), 4.19 (d, lH), 4.64 5.19 (s, lH), 5.5 (m, lH), 6.07 (d, lH) , 7.11 7. L8 (b,! H), 7.41 (t, lH), 7.6 (d, lH), 8.03 Binding — Binding_ Central Ministry of Economic Affairs Bureau of Staff Consumer Cooperatives-(m, 2H), only-( 4,6-Two (1 »pyridine-: 1-yl)-: 1,3,5-tris-2-yl)-« '-(2- (3-5-methyl-7- (3 -Nitrophenyl) -8-ethoxycarbonyl), 1 «NMR (200 MHz) S 1.26 (t, 3H), 1.84 (m, 4H), 1.96 (m, 8H), 2.33 (ra, 2H), 2.58 (s, 3H), 2.81 (πι, βΗ), 3.52 (rn, 16H), 3.83 (m, 2H), 4.11 (m, 4H), 4.18 (d, lH), 4.63 (d, lH), 5.19 (S, 1H), 5.5 7.15 (b, lH), 7.42 (t, lH), 7.59 (d, lH), 8.05 (m, 2H), N- (2,6-Second (ttt pyrrolidin-1-yl) pyridin-4-yl) -N,-(2- (3- (5-methyl-based paper standard applicable medium valve S homework standard (CNS) A 4 specifications (210 X 297 mm) 31 212601 V. Description of the invention (20) -7- (3-chlorophenyl) -8-ethane gas carboxyl), 1h NMR (200 MHz) S 1. 26 (t; 3H), 1.84 (m, 4H), 1.95 (m, 8H), 2.35 (m, 2H), 2.59 (s, 3H), 2.82 (m, 6H), 3.52 (m, 16H) ; 3.83 (m, 2H), 4.13 (m, 4H), 4.19 (d, lH), 4.64 (d, lH), 4.86 (s, ΙΗ), 5.18 (S, 1H), 5.48 7.23 (m, 5H) , N- (3,6-II (diethylamino) pyridine-2-yl) -N,-(2- (3- (5-methyl-7- (3-aminophenyl) -8-ethyl Gas carbonyl), 1h NMR (200 MHz) 5 0.96 (t, 6H), 1.04 (t, 6H) (1.26 (t, 3H), 1.83 (m, 4H), 2.33 (m, 2H), 2.59 (s, 3H), 2.79 (m, 6H), 2.99 (q, 4H), 3.51 (m, 12H), 3.83 (ra, 2H), 4.13 (m, 4H), 4.21 (d; 1H), 4.66 (d, lH ), 5.21 (s, 1H), 5.48 (m, 1H), 6:06 (d,! H), 7.11 (d; lH), 7.23 (m, 5H), (please read the notes on the back of Qi first Write this page again) i. Binding. Ordering. Printed by the Central Standards Bureau WK Industry and Consumer Cooperative 1 ^-(4,6-Wu ((11; Gedian-1_Base) _. 1,3,5-Sanshu-2-yl) _ ^ 1 '-( 2- (3- (5-Methyl-7- (3-Aminophenyl) -8-ethoxycarbonyl), MMR (200 MHz) S 1.25 (t, 3H), 1.84 1.95 (m, 8H), 2.33 (ra, 2H), 2.59 (s, 3H), 2.8 (m; 6H); 3.5 (m; 16H), 3.83 (m, 2H), 4.15 (m, 4H), 4.2 (d, lH), 4.65 ( d, lH), 5.21 (S, 1H), 5.5 (m, lH), 7.23 (m, 5H), N- (2,6-¾ (¾ pyrrolidin-1-yl) piperidin-4-yl) -H,-(2- (3- (5-methyl7-cyclohexyl-8-ethoxycarbonyl)), this paper is again applicable to the Chinese National Standard (CNS) A 4 specifications (210 X 297 public: $) 22 .Line. Λ6 B6 2l2d〇 ^-V. Description of the invention (21), 1R NMR (200 MHz) ^ 0.99 (m7 6H), 1,26 (t, 3H), 1.51 (m; 5H); 1.84 (m, 4H), 1.95 (m, 8H), 2. 33 (m, 2H), 2.6 (s, 3H), 2.81 (m, 6H), 3.51 (m, 16H), 3.83 (m, 2H), 3.91 (d, lH), 4.13 (m, 4H), 4.19 (d, 1H), 4.64 (d, lH), 4.86 (S, 1H), 5.5 7.2 (b, lH), H- (3, 6-Two (Diethylamino) pyridine-2-yl) -N '_ (2-(3-(5 -methyl-7 cyclohexyl-8-ethanecarbonyl)), * (Please read the precautions on the back first Write this page)

1H NMR (200 MHz)S 1 (m,12H), 1.05 (t,6H), 1.25 (t,3H), 1.5 (m,5H), 1.83 (m;4H), 2.33 (rn,2H) , 2.59 (s,3H), 2.8 (m,6H), 2.98 (q,4H), 3.51 (m,12H), 3.83 (m,2H), 3.91 (d,lH), 4,13 (m,4H), 4.2 (d,lH), 4.65 (d,lH); 5.48 6.06 (d,lH), 7.1 (d,lH), 7.16 (b,lH), -装. 'ΤΓ. 許(4,6-贰(吡咯啶-:1-基)-1,3,5-三唞-2-基)-«'-(2-(3-( 5 -甲基-7 -琢己 基-8-乙 氣羰基 ), 1 1h NMR (200 MHz) S 0. 98 (m,6H), 1.25 (t,3H), 1.51 (m,5H), 1.83 (m,4H), 1.94 (m,8H), 2.34 (tn,2H), 2.59 (s,3H), 2.8 (m,6H), 3.51 (m,16H), 3.83 (ra,2H), 3.9 (d,lH), 4.13 (m,4H), 4.19 (d,lH), 4.64 (d,lH), 5.5 (m,lH), 7.2 (b,1H). 衣纸張尺度適用中1¾¾家作準(CNS)甲.1規格(210 X 297公;Ϊ ) 23 經濟部中央標準局貝工消费合作社印S-R.1H NMR (200 MHz) S 1 (m, 12H), 1.05 (t, 6H), 1.25 (t, 3H), 1.5 (m, 5H), 1.83 (m; 4H), 2.33 (rn, 2H), 2.59 (s, 3H), 2.8 (m, 6H), 2.98 (q, 4H), 3.51 (m, 12H), 3.83 (m, 2H), 3.91 (d, lH), 4,13 (m, 4H), 4.2 (d, lH), 4.65 (d, lH); 5.48 6.06 (d, lH), 7.1 (d, lH), 7.16 (b, lH),-installed. 'ΤΓ. 许 (4,6-Two ( Pyrrolidine-: 1-yl) -1,3,5-tris-2-yl)-«'-(2- (3- (5 -methyl-7 -trihexyl-8-ethanecarbonyl)), 1 1h NMR (200 MHz) S 0.98 (m, 6H), 1.25 (t, 3H), 1.51 (m, 5H), 1.83 (m, 4H), 1.94 (m, 8H), 2.34 (tn, 2H ), 2.59 (s, 3H), 2.8 (m, 6H), 3.51 (m, 16H), 3.83 (ra, 2H), 3.9 (d, lH), 4.13 (m, 4H), 4.19 (d, lH) , 4.64 (d, lH), 5.5 (m, lH), 7.2 (b, 1H). Applicable paper size standard is in 1¾¾ National Standard (CNS) A.1 specification (210 X 297 g; Ϊ) 23 Central Ministry of Economic Affairs The Bureau of Standards printed the SR.

Claims (1)

(請先閱讀背面之注意事項再填寫本頁) 毯濟部中央標準局員工消費合作钍印- 其中: R為(C1-C4)院基; Ri為游離或鹽化羧基,q - C4-烷氣羰基,烯丙氧羰基,或 如式-C Ο N Η - C Η 2 - C Η 2 - 之基; 1?2為((^-〇7)環烷基,《,)8或7-吡啶基,被鹵原子或硝 基取代之苯基諸如取代有2-氛、3-氛、4-氛、2,3-二氱, 2- 氣、2-氣-3-氛、2-硝基、3-硝基、4-硝基,或4-氣-2, 3- 二氱之苯基; R3為游離或鹽化羧基或4 - C4-院氧羰基; D為具1-3値氮原子之5-或6-員雜環,其視情況可取代以1 或2個胺基、單-(q - C6烷基)胺基、單-(C3 - C7烯基)肢基、 、二-(q-k烷基)胺基、(q-c6烷基)-(c3-c7烯基)胺基 、六氫吡啶-卜基、嗎唞-4 -基、%咯啶-1 -基,以及其醫 藥上可接受之鹽,單一對掌異構物,消旋物及非對映異構 衣纸張又度適用中gS家f?準(CNS)甲4規恪(21ΰ X 297父贷&gt; ^ B7 C7 D7 六、申請專利範園 (請先閲讀背面之注意事項再填寫本頁) 物混合物。 2. 如申請專利範圍第1項之化合物,其中D選自包含下列 基之族群:[2,6-貳(二乙基胺基)嘧啶-4-基]、[2,6-貳(2 -丙烯基胺基)嘧啶-4-基]、[2,6 -貳(胺基)嘧啶-4-基]、[ 2,6 -貳(tft咯啶-1-基)嘧啶Γ 4-基]、[4,6 -貳(2 -丙烯基胺 基)-1,3, 5-三唞-2-基]、[4,6·.貳(二乙基胺基)-1,3,5 -三 唞-2-基]、[4 , 6-貳(吡咯啶-1 -基)-1 , 3 , 5-三唞-2-基]、[ 3,6-貳(二乙基胺基)«啶-2-基]、[3,6-貳(吡咯啶-:1-基) 吡啶-2-基]、[3,6-貳(2-丙烯基胺基)吡啶-2-基]。 3. 如申請專利範圍第1或2項之化合物,其中&amp;及1?3皆為 q-Cf 烷氣羰基,或!^;^(:ΟΝΗ-(:Η2-(:Η2-Ν^] , R2 如前文 定義,以及R為甲基。 4. 一種對呼吸道有抗氣喘及抗發炎活性之蕖學組成物, 其含有一種或以上如申諳專利範圍第1項之式(I )化合物 以及適當賦形劑。 經濟部中央標準局3工消費合作社印&quot; 本纸張XJt迺用中S3家橒準(CNS)甲4現格 (210 X 297公犮&gt; 〇(Please read the precautions on the back before filling out this page) Blanket Ministry of Economy Central Standards Bureau employee consumption cooperation thorium printing-where: R is (C1-C4) courtyard; Ri is free or salted carboxyl group, q-C4-alkane Gas carbonyl, allyloxycarbonyl, or a group such as -C Ο N Η-C Η 2-C Η 2-; 1? 2 is ((^ -〇7) cycloalkyl, ",) 8 or 7- Pyridyl, phenyl substituted by halogen or nitro such as 2-atmosphere, 3-atmosphere, 4-atmosphere, 2,3-di-trim, 2-gas, 2-gas-3-atmosphere, 2-nitro Group, 3-nitro group, 4-nitro group, or 4-gas-2,3-ditriphenyl group; R3 is free or salted carboxyl group or 4-C4-homooxycarbonyl group; D is 1-3. 5- or 6-membered heterocyclic ring of nitrogen atom, which can be substituted with 1 or 2 amine groups, mono- (q-C6 alkyl) amine group, mono- (C3-C7 alkenyl) leg group,, Di- (qk alkyl) amino group, (q-c6 alkyl)-(c3-c7 alkenyl) amine group, hexahydropyridine-butyl group, mol-4-yl group,% pyridine-1-yl group, As well as its pharmaceutically acceptable salts, single palmate isomers, racemates and diastereomeric coating papers, it is also applicable to the gS family f? Quasi (CNS) A 4 regulations (21ΰ X 297 father loan &gt; ^ B7 C7 D7 VI. Application for a patent garden (please read the precautions on the back before filling in this page) 2. Compounds as described in item 1 of the patent application, where D is selected from the group containing the following groups: [2,6- Two (diethylamino) pyrimidin-4-yl], [2,6-two (2-propenylamino) pyrimidin-4-yl], [2,6-two (amino) pyrimidine-4-yl Group], [2,6 -2 (tft pyridin-1-yl) pyrimidine Γ 4-yl], [4,6 -2 (2-propenylamino) -1,3, 5-trison-2 -Yl], [4,6 ·. II (diethylamino) -1,3,5-tris-2-yl], [4, 6- II (pyrrolidin-1-yl) -1, 3, 5-tris-2-yl], [3,6-two (diethylamino) «pyridin-2-yl], [3,6-two (pyrrolidin-: 1-yl) pyridine- 2-yl], [3,6-two (2-propenylamino) pyridin-2-yl]. 3. If the compound of patent application item 1 or 2, wherein & and 1? 3 are both q -Cf alkane carbonyl, or! ^; ^ (: ΟΝΗ-(: Η2-(: Η2-Ν ^), R2 is as defined above, and R is methyl. 4. A kind of anti-asthmatic and anti-inflammatory activity on the respiratory tract The chemical composition, which contains one or more formulas as described in Item 1 of the patent scope ( I) Compounds and appropriate excipients. Printed by the Central Standards Bureau of the Ministry of Economy, Industry, and Consumer Cooperatives. "This paper XJt is used in the Chinese S3 home standard (CNS) A 4 current format (210 X 297 Gongluo> 〇
TW081109698A 1991-12-06 1992-12-03 TW212801B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI913269A IT1252626B (en) 1991-12-06 1991-12-06 ¬3H, 7H | THIAZOL ¬3.4A | PYRIDINS WITH ANTI-ASMATIC AND ANTI-INFLAMMATORY ACTIVITIES OF THE AERIAL ROUTES

Publications (1)

Publication Number Publication Date
TW212801B true TW212801B (en) 1993-09-11

Family

ID=11361270

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081109698A TW212801B (en) 1991-12-06 1992-12-03

Country Status (4)

Country Link
AU (1) AU3084292A (en)
IT (1) IT1252626B (en)
TW (1) TW212801B (en)
WO (1) WO1993011134A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2210633C2 (en) * 1972-03-06 1983-09-22 Bayer Ag, 5090 Leverkusen Condensed pyridine derivatives, processes for their preparation and pharmaceuticals containing these compounds
WO1987000836A1 (en) * 1985-08-06 1987-02-12 Boehringer Biochemia Robin S.P.A. Pharmaceutically active 2-thiomethyl-substituted-1,4-dihydropyridines
IT1249210B (en) * 1990-06-08 1995-02-20 Boehringer Mannheim Italia ¬3H, 7H | Thiazole-¬3,4-A | PYRIDINES WITH ANTIASMATIC AND ANTI-INFLAMMATORY ACTIVITIES OF THE AERIAL ROUTES

Also Published As

Publication number Publication date
AU3084292A (en) 1993-06-28
ITMI913269A1 (en) 1993-06-06
WO1993011134A1 (en) 1993-06-10
ITMI913269A0 (en) 1991-12-06
IT1252626B (en) 1995-06-19

Similar Documents

Publication Publication Date Title
JP3218037B2 (en) Heterocyclic amines useful for treating asthma and respiratory inflammation
JP5697163B2 (en) Substituted 3-hydroxy-4-pyridone derivatives
JP2004521872A (en) New pyridine-substituted pyrazolopyridine derivatives
US20090306169A1 (en) Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors
AU6143899A (en) Fused pyridine inhibitors of cgmp phosphodiesterase
HU211647A9 (en) Phenylcarboxamide compounds which have useful pharmaceutical activity
RU2522578C2 (en) Phenylpyrimidone derivatives, pharmaceutical compositions, methods for preparing and using them
EP0513379A1 (en) 2-arylthiazole derivative and pharmaceutical composition containing the same
JP2004517827A (en) New carbamate-substituted pyrazolopyridine derivatives
US20080090851A1 (en) Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) Bicyclic Heteroaromatic Compounds
CN105492434A (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
US6077841A (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
Jones et al. Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent
JP2007522146A (en) Α4 integrin-mediated cell adhesion inhibitor for the treatment or prevention of inflammatory diseases
DK156722B (en) ANALOGY PROCEDURE FOR PREPARING 2-PIPERAZINOPYRIMIDINE DERIVATIVES
TW212801B (en)
US5753671A (en) Imidazopyridine derivatives as dual histamine (H1) and platelet activating factor (PAF) antagonists
NO167031B (en) ANALOGUE PROCEDURE FOR PREPARATION OF 1H, 3H-PYRROLO (1,2-C) -TIAZOLD DERIVATIVES
JP4629105B2 (en) Benzyloxy derivatives as MAOB inhibitors
NO171908B (en) ANALOGY PROCEDURE FOR PREPARATION OF 4- (AROYLAMINO) PIPERIDINBUTANAMIDE DERIVATIVES
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
WO1989005295A1 (en) Acyl derivatives of hydroxypyrimidines
CA2084669C (en) [3h,7h]thiazolo[3,4-a]pyridines with antiasthmatic and a antiinflammatory actions on the respiratory tract
EP1597234A2 (en) Novel compounds